🎁 Black Friday: up to 50% off of annual plans
Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
13,210
-120 (-0.90%)
Nov 20, 2026, 1:48 PM IST
← View all transcripts

R&D Day 2026

Nov 11, 2026

Summary

The strategy centers on validated science, differentiated products and faster development, with a broad pipeline and launches planned through 2030. Innovative revenue is projected at $6B–$7B in 2030, supported by increased R&D investment and disciplined capital allocation.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Good morning, everyone. Thank you for coming to Teva's R&D Day 2026. We are very happy to Welcome all of you here to New York City. For those of you joining in virtually, we would like to thank you as well. Before we get started, just a few housekeeping items. For those of you here in person, please turn off or silence your mobile devices. That is very important. We will have time for Q&A after the presentations, and we ask that you please hold your questions until then. We will have plenty of time for questions. For those joining the webcast, you will be able to submit questions via the webcast as well, and there will be instructions on the platform at that time. Most importantly now, please note that today's presentations and Q&A include forward-looking statements, including about our pipeline, clinical programs, and regulatory timelines.

These involve risks and uncertainties, and actual results may differ materially. Risk factors are described in our latest Form 10-K, Forms 10-Q, and earnings press release. Statements are made as of today, and we undertake no obligation to update them. We may also discuss certain non-GAAP measures. A reconciliation to the most directly comparable GAAP measure can be found on our website. Quickly, let me walk you through what to expect on the agenda today. We will start with Richard Francis, who will put today's discussion in the broader context of Teva as a leading biopharmaceutical company and where we are in our Pivot to Growth strategy, and where we see opportunity ahead. Eric Hughes will then come and take you inside what we mean by high-velocity biopharma, how the way we operate, make decisions, and execute is enabling us to move with greater speed and focus.

Steffen Nock and David Gardiner will go deeper into our high-value pipeline, including the early and late-stage programs and assets. We will then turn to unlocking more value with Chris Fox, looking at how we are maximizing the potential of our existing assets and creating additional opportunities for patients and for Teva. Eli Kalif will then walk us through the big picture of Teva's current and future financial outlook and acumen. Finally, Richard Francis will bring it all together, including what this portfolio and pipeline mean for Teva. Then we will have the Q&A session. With that, it is my pleasure to introduce Teva CEO, Richard Francis.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Thank you, Chris. Welcome, everybody. Thank you so much for coming here today, so early in the day, to Teva's first R&D Day. It is interesting because I was on this stage three and a half years ago, and actually some of you were in the audience, so welcome back, where we launched the Pivot to Growth strategy, a strategy that was put in place to transform Teva from a pure-play generics company to a world-leading biopharma company. That strategy became very much our North Star. Everything we did every day, every week, every month was focused on that strategy. It was a very specific strategy. It was very detailed. What I would say about that, there is good and bad in that. The good is you know exactly what to do, when to do it.

The bad is everybody else knows exactly what you're planning to do and when you're planning to do it. The ability to be evaluated and measured is really clear. But we're okay with that. We've been okay with that on this transformation, and we'll be okay with that going forward. Now, when we talk about what we're going to go through today, it's very much that transformation from a pure-play generics to a world-leading biopharma company. While that statement, I think, was a challenging statement to communicate three and a half years ago, I think, and I'll explain why, it's less so today. You're going to hear about our pipeline and the transformation of our pipeline.

The fact that whether it's early or late stage, you're going to get some insights from Eric as to how we've done it so quickly, and our approach to our R&D, which I think is a slightly different strategy from others, and what that has actually given us in terms of results. Then you can actually see the value that we create out of that pipeline, because having a pipeline and bringing it to market is one thing, but being able to maximize it and optimize it is really important. And we give you proof points of what we've done and what we will do. Now, when we think about this strategy, as I said, it's our North Star. And this is the slide that I presented three and a half years ago on this stage.

This is the exact slide, which is why it looks a bit dated and not as fancy as the new slides. But I tell you this, and I show you this, and many of you I talked to on a regular basis, I walk through all of these pillars every time. This is how we execute and operate at Teva. We have clear North Star, we know where we're going, we have a clear plan to get there, and we execute relentlessly across all of these pillars. Operations, we love. We love the execution. We love the focus on moving things forward. And you'll see that today. Now, this is what we set out to do. And as I said, when I presented that three and a half years ago, it was very detailed, but it did have a level of skepticism from the audience, I remember.

Where we ended up. Well, I wouldn't just say we've met our commitments. I'd argue that we've over-delivered significantly on many of these commitments. And I remind you that there was real ambition in what we set out to do. One of the things you're going to hear about today is how we did it, which I call the Teva way. It's about our people and our culture. To move a company so quickly to where we have, to do so much in such a short space of time, you can only do if you have great people and a great culture. And you'll hear that from all of the people on stage today. But if you look about just the numbers, because I can talk about things, but I think I've got an audience of people who are very much focused on the numbers.

The numbers are, in 2022, we ended the year with innovative sales of $1.3 billion. We are now going to end the year with $3.8 billion to $3.92 billion. AUSTEDO was doing less than $1 billion in 2022. It is going to do $2.5 billion this year, which is a year ahead of schedule, which was seen as a stretch. In the meantime, we have launched UZEDY, and we have just recently launched WELTRUZA, our long-acting olanzapine. In the meantime, despite the capital constraints we have had with the necessity to pay down debt, we have allocated capital, and we have done two deals. We have done a deal with Emalex with ecopipam, and we have done a deal with BioXcel with dexmedetomidine. At the same time, on step-up innovation, something which people really questioned us about, can you drive innovative pipeline?

We have taken a pipeline, we have radically changed it, we have 10 assets in the pipeline, and we move at pace. Pace is really key. You will see the appetite we have to move fast will continue. We have had six positive clinical readouts, all in the space of three and a half years. When it came to our generics business, that was one that had a lot of discussion three and a half years ago. Now, not a lot less, which sometimes disappoints me, because the radical change in that business has occurred. We started with stabilizing the business, and now we have changed the portfolio completely. We had six biosimilars in 2023. We have 32 now. We have 15 in the market, and we keep doing more deals and more partnerships. We have changed the whole portfolio makeup.

When it comes to focus the business, this was all about capital allocation. Put the capital where it gets the best return, best short, medium, and long-term return. By the way, to do that in a capital-constrained company means you have to have real discipline and make real choices. To drive this pipeline, to drive these innovative products, we had to allocate capital, which means you had to take it from somewhere else. That allowed prioritization. That allowed focus within the organization. You are starting to see that, but some of the things that have come out, we committed to being investment grade by the end of 2027. We have already done that a year ahead of schedule. Instead of a year ahead of schedule.

One I missed, our biosimilar business, we said we are going to double that by 2027, and we have doubled it by the end of 2026. From a free cash flow point of view, the company has been transformed. I would argue, and I would ask you maybe, to look at the free cash flow as the presentation goes on, because this is something people need to start to understand and recognize. That is what we did. That has been driven in a very short period of time. What does that mean? Where are we on this journey to becoming a biopharma company? I am very much a numbers guy, so as much as I will talk about things and highlight things in a strategic way, it all comes back to the numbers, and the numbers will always tell you the truth.

The reality is, we have transformed this company. It is no longer a pure-play generics company. It is a biopharma company, I would say a world-leading biopharma company already. Our innovative revenue is not only doubled, it has almost gone up three times to $3.92 billion at the end of this year. The growth trajectory of that, you will see through the presentation, is significant, and the amount we have in our pipeline is significant. That pipeline can deliver over $10 billion of peak sales. What you will also see is the probability of that pipeline maturing actually coming to market, and that is an important part to take into account. How have we done this?

I often get asked, "How do we do this in such a short space of time?" I would argue it is the right people in the right place with the right culture and the right plan, and then you just execute. There are some subtleties to it, and maybe I will talk to you through a bit about how we have done that. You have heard this term already, a high-velocity biopharma company. What does that mean?

I have worked in both biotech, I have worked in both startup, and I have worked in big pharma, and they all have appealing attributes. What you will find at Teva is we have combined those two. The speed and agility of a biotech company, but the scale, the capability, and the discipline of a world-leading biopharma company, we brought them together. What does that mean? It means we create a different approach to how we run the business.

From R&D, excuse me, you will hear from Eric about his different approach to R&D, which is based on the fundamentals of picking assets with a high probability of success based on either the target has been validated, we know the mechanism of action. Whether that science comes internally or externally, we are agnostic. We do not believe in-house is better than external. We just focus on the asset. The other part, which is critical, is accelerated development. Having the right product in your pipeline is only valuable if you get it to market as soon as possible. Because then you can just start to generate revenue, which means then you can start the cycle again. When it comes to the middle part, decisive decision-making and capital allocation, we do this across the business regularly. We do not have an end-of-year AOP where we allocate capital. It is real-time.

When Eric turns over some data, we go straight away there and then, and we allocate capital, which means we have to take it from somewhere else. So we are constantly evaluating the return on capital deployed, constantly, and the company know that. He will give you some great examples of how quickly we moved on certain situations. This also applies to our commercial assets. When we have a commercial asset that is doing particularly well, and maybe it surprised us, we put more capability behind it, we put more capital behind it, more resources. We do not wait for the end of the year. We operate in real-time. That sort of links to the final part, strong commercial capabilities. I would argue that a product in Teva's hands will always be maximized more than anybody else. That is a pretty bold statement, okay?

But what I am going to show you some data as to why I believe that, and it is based on the fundamentals of great planning, great people, and great execution, things we take very seriously and have a lot of pride in at Teva. That is how we do it. What is the proof of the pudding? That sounds pretty nice. It sounds like a thing a CEO would say. But where is the substance? At Teva, we are all about substance, we are all about data. Let us talk about the pipeline. This is what the pipeline looked like when I came in. I sat down in Eric's office in Parsippany, I looked at it, and I was pleasantly surprised. I said, "These look like they could be pretty good assets. How are they doing?" Eric agreed. He said, "Yeah, I was the same when I came in.

These are pretty good." We looked through the progression through where they were in the clinic, and it was at snail's pace. We said, "This fundamentally has to change. We have to increase this. We have to get WELTRUZA in phase III moving fast. We have to recruit more patients. We have to move duvakitug, which I think had recruited six patients in phase II. We need to accelerate that for a mid-interim analysis in the middle of 2024." Which, by the way, we did a full analysis by Q4 2024. We talked about it, and I talked about the value that would bring to the company, the opportunity that would bring, and Eric clearly had the same mindset.

So then it was about allocating capital and capability, building capability, giving the capital, giving the money to, and then changing the ambition, as we fundamentally changed the ambition. Every time we talked, it was about how fast we could make WELTRUZA go through the clinic, how fast we could move duvakitug, and how fast we could move our other programs. It became a drumbeat. By the way, I am so proud of that. I am so proud of the fact that we have great products coming to market now because the actions we took in 2023 and the change we made in 2023 made this happen. What does it look like three and a half years on? I mean, this is, I think, a drastic change from where we were. I would ask you to focus on a few things on this slide.

Not only have we moved things really quickly, so we have picked up the pace and the speed of our pipeline, but we also expanded it significantly, and the quality of it. There are a few things that I would like to draw your attention to on this slide. One is, our neuroscience franchise now has grown significantly. If you put these assets together, WELTRUZA, UZEDY, dexmedetomidine, and ecopipam, we have potential here of over $7 billion in a neuroscience, where that was not even being discussed three years ago. The other thing, which is really unique, and I have never had in my career, I have always wanted to have one pipeline in an asset. We have four. We have duvakitug at TL1A, we have anti-IL-15, we have PD-1/IL-2, which you are going to hear a bit about today, and then we have the TSLP/IL-13.

All of those are homegrown, so super impressive. That is what we have done with the pipeline. That is what that Teva way, that is what that high-velocity biopharma, that is what, when you put a biotech and a big pharma together, what you can achieve. As I said, having great pipeline is one thing, but you have to optimize it and maximize it. This transformation, I think, is remarkable. $1.3 billion-$1.383 billion, $3.92 billion, based on our November 1st forecast for this year. That is dramatic. What I would also highlight is the fact that when we started this journey, and obviously there are many analysts in the room, thank you for attending, and this is no way a criticism, the average was $1.4 billion peak sales.

We are going to do $2.5 billion this year, and we believe it is going to do over $3 billion going forward. UZEDY, and I am pointing these out because these were not slam dunk products. UZEDY, launching a long-acting risperidone into a market that is super crowded. We have doubled that market share of long-acting risperidone, and we have grown that product extensively. AJOVY, something we never talked about. I think it had gone off the radar. We have taken a product from $400 million to over $900 million this year, and we are going to do over $1 billion. That is a 30% CAGR. I remind you of that because, once again, what does this company mean? What does that culture mean? What does that approach mean? It means you can take assets like this, who are high-quality assets, and really maximize them.

These assets in themselves, I want to make sure people understand, we believe have a value of $5.5 billion. These assets are going to keep growing, so keep that in mind as I come onto some other slides. We have some assets that are growing fast that are coming on the market, but we have a wave of launches coming, and we have a launch every year till 2030. After that, we have a launch, depending on how quickly Eric moves, every 14 - 18 months. That is extraordinary. I would also say that many of these assets, because we know the mechanism of action, we have seen some great data, have a very high probability of coming to the market.

That means in 2030, we are going to have nine innovative assets on the market, with all potential over $1 billion each, and we can debate exactly what they should be. But that is transformative. What does that look like from a revenue point of view? I apologize a bit for this slide, because I realize in 2025, we did show revenue for 2030, and the number was considerably smaller, which questions our forecasting capabilities a little bit.

In my defense, I would say, one, we have acquired two products that I mentioned, and we have accelerated some products which were even beyond my wildest hope, and I am pretty ambitious when it comes to numbers. But look at this cadence. We have doubled it to the end of this year. We are going to potentially double it again by 2030, and then double-digit growth we are going to have coming forward after that.

It is clear based on the pipeline you are going to hear today. Do not forget, some of this will launch between now and 2030. That growth is going to. We do not have a significant LOE on the horizon. What is this going to do? It is going to transform our portfolio. When I said we are no longer a pure play generics, we are a world-class biopharma, it is based on our portfolio. Our innovative portfolio will be of scale. What that does, here is another area I would ask you to look into when the presentation comes to Eli's presentation, is what this does for our gross margin. Our gross margin gets transformed from 55% where it is today, and every year it will be pulled up. We will stay very much disciplined on our OpEx, which means we will continually grow our profitability.

We will grow our EPS, and we will grow our cash flow. What does that look like? A radically different company than we started out on this journey in 2022, at the end of 2022. Radically different. Once again, this is not a slide of hope. This is not a slide of potential, could be, maybe. 2030 will happen, because everything we need to do to make it happen, we already have in action now. When you look at what it means, what $6 billion-$7 billion of innovative revenue means, it means we have nine innovative assets on the market, but it also means that our free cash flow changes dramatically to over $3.5 billion. That changes our options, ability to invest more in our pipeline, invest more in our infrastructure, drive more growth, drive more profitability, do more business development.

We have not had all of that optionality going forward, but what I will say is the discipline to capital allocation will stay true. Whether that is allocated internally, allocated to acquisitions, or returned to shareholders, we will always be thinking about how we make that capital work hard. That is a fundamentally different company. As you hear today from the team, hopefully I have given you an insight into where we came from. The reason why I looked back, somebody said to me, "Do not look back. Just keep looking forward." I said, "I think we have to get credibility for people to understand why we are so positive about the future." The credibility is defined by what we have done in the past. What we said we were going to do, we did.

We are going to tell you what we are going to say, we are going to tell you what we are going to do over the next 5-10 years, and we will do it. As you think about what is coming forward, remember what we have done. I would say, and I genuinely believe this, the upside for Teva going forward is as great as it was over the last three and a half years, but probably carries a lot less risk. I am going to hand you over to my very capable team. We have a few extra faces on this slide than normal. I will go back to, this transformation has happened because we had people aligned behind a strategy who were passionate about it and executed it. This team, you are going to hear how aligned we are and how aligned we are culturally.

You are going to hear the theme of speed, decision-making, and ambition. You are going to find the fact that we work in a matrix organization, so we do not let functions get in the way. We follow assets, we follow the strategy, and this is what you are going to hear from this team. Super proud of what they are going to present. Super excited by your reaction. So with that, without further ado, I am going to hand it over to Eric Hughes, Head of R&D.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

I love when Richard goes over the last almost four years, because it gets me excited, and really, I have never seen a transformation in an R&D organization like that before. Before I get into the whole exciting part about how we think about R&D a little bit differently, I think the through line here is, Teva had a culture when I first got here, and Richard kicked off the Pivot to Growth, where the culture allowed that change in mindset from the days before and to now where we are today. I think that what made it possible was the culture and the people at the company, without a doubt. Here are the three pillars I am going to talk about. It is simple, but it is all about how we executed on and made it happen.

We focus first on patient impact, unmet medical need, and then using proven science to help those people. Second, we will focus on differentiated products. Steffen will talk a lot about how we make antibodies and engineer proteins, which is, I will admit, is better than almost everyone I have been at. They really put an extra mile into it. I will also add, and I was going to save this for later, if you have ever launched a non-differentiated product, you never want to do that again. We ruthlessly make sure we are differentiated. Finally, and almost as important as the patients we serve, is the speed in which we execute on it. You have to think differently about how you compress timelines and get rid of the white space in development. David will talk a little bit about that.

David and I cut our teeth in the same way in the craziness of hepatitis C, and I will tell a little bit about that when I introduce him. It is a mindset, it is a focus on patients using proven science, it is making differentiated products, and then executing with speed. The burden of disease, the patients' unmet medical need, the impact we make.

Look at this slide. We have a ruthless focus too. You never want to diverge from what you want to work on, what therapeutic areas you want to become expert in. Neuroscience is a fantastic heritage at Teva, and we are executing it extremely well. Chris's team in the U.S., it is remarkable how well they have driven the in-market products. Immunology, I think there is a secret expertise we have at Teva, which is a natural organic growth of a future wave of molecules at Teva.

I am really excited by the pipeline that is coming up, and he will talk a lot about not only things that we have proven we do well, but what is coming up behind it. A ruthless focus in these therapeutic areas on unmet medical need. I will bet everyone in this room knows someone who has schizophrenia, agitation, Tourette's, or asthma, or inflammatory bowel disease, vitiligo, or celiac disease. I am certain. So the impact we can have at Teva is magnificent. It is massive. But what do I mean by proven science? Our industry has not done a very good job at speed and lowering costs, and I think that everyone in this room gets frustrated with that sometimes. So, one of the ways I think about it, the way my team thinks about it, is we know the science.

There is science out there that is clinically proven, there is science that is very strong, and then how can we differentiate and bring that science together? I think TL1A, that is a differentiated, novel asset that has clinical proof, and every day we are learning more about it, and has a fantastic future. We were at the beginning of that race for TL1A. Anti-IL-15, we have been following the science now for a while. We have been helping add to that scientific knowledge. I think that is another de-risked asset at this point. But then look at PD-1/IL-2, TSLP/IL-13, and the new one we will talk about today, TL1A/IL-23. These are known targets, known MOAs. For me, it is not a matter of whether these work, it is how much better can we advance the science and the care for patients with these different MOAs.

I am very bullish on the way that we choose our targets and then how we execute on them. But we do not stop there. We make good molecules, we focus on great unmet medical need, but we maximize each one of these products. There are a couple examples here. One of the things I love about inflammatory diseases is once you have got a good molecule with a good safety profile, you can then knock out indication after indication, and really change the science and the clinical practice of medicine in these things. Duvakitug, anti-IL-15, TSLP/IL-13. These are the typical thing we say, a portfolio and a product. So there is a lot there that we can continue to maximize. We do not stop too with our inline neuroscience. AJOVY was the first mAb program for pediatrics that succeeded in phase III.

DARI, pediatrics is critical to the launch of DARI because 25% of kids have the asthma out there. Then UZEDY, we got bipolar. We did not even run a study. We did it all on modeling and simulation. So we continue to maximize the populations we look at. Then the thing I get really worked up for Teva is our formulations and devices group. They are stellar at Teva. The value you can build into a program just on that knowledge is magnificent. WELTRUZA, by definition, is all about the formulation, that incredible value. AUSTEDO, we made the once-a-day molecule with a really advanced formulation. That really helped Chris drive the sales with the titration pack and the once-a-day dosing for AUSTEDO. Then DARI. Making inhalation devices is not easy, guys.

We have a dual-action dry powder inhaler, which is extra hard to make, and that is a benefit for patients. So total differentiation based on true expertise at Teva. I just told you about the patient impact that we focus on and how we use proven science to get us there to help patients. The next thing, I have already obsessed a little bit about this with you, is about differentiating the products that we launch. Every one of our programs that we are working on is fitting a niche or an area that is an unmet medical need and is different from the others. Let me walk you through a few of those that we have right now. First, in neuroscience, WELTRUZA, I mean, when you look at WELTRUZA, I think about UZEDY.

UZEDY, when we looked at that, I saw, boy, a subcutaneous injection, no loading dose, no titration, room temperature delivery. It looked like a really good profile, but we were all nervous because we were going into such a crowded field. It has done incredibly well. I mean, it is kudos to the commercial team for how well that has penetrated the market. That tells me that that formulation type is a real true gem, and WELTRUZA is a perfect. It is almost made for WELTRUZA, because it builds upon olanzapine and really is going into a place where there is no real viable option, and that is 20% of the oral market. So WELTRUZA is a great example of a formulation best-in-class differentiated molecule. Ecopipam, I will need to remind you, that is a brand new MOA. That is a D1 antagonist.

That is completely new, and it is the first time you have ever launched a drug for Tourette's, it is dedicated to Tourette's. So it is by definition all differentiated. Finally, dexmedetomidine. This is this new molecule for agitation, which I am super excited about because that fits in so nicely. There is no other rapid sublingual treatment that you can use at home that can start having activity within 20 minutes. That is great stuff, and that is our neuroscience population. In immunology, it is all differentiated.

DARI, I mentioned, we will have pediatrics in the label. We will have a dry powder inhaler that is easy for kids to use, even for adults who have trouble timing an inhaler. So great product. Duvakitug, most potent, most selective, lowest anti-drug antibodies. We have recorded the best results in phase II. It is differentiated. I am really excited about that entirely novel class of biologic. Then finally, anti-IL-15. I am really excited about that one.

I mean, we started with a great molecule. It is a 38-day half-life. It is once a quarter dosing. It is in chronic diseases, and we have seen really big changes in what we can do for vitiligo and celiac disease. So, I am proud to have a differentiated product because at the end of the day, the efficacy will be great, but we will also have something that people can use conveniently. So I am really proud of these late-stage assets that we have in development, all differentiated. We have a good proven track record in neuroscience. I get worked up about these in market. AUSTEDO, UZEDY, AJOVY, and WELTRUZA, the new kid. As Richard mentioned, we do not care where the innovation comes from.

We license, we partner, we move things forward and make things better, and that really results in what we see in the markets, because then it drives what the patient need and what they want. Great proven track record in neuroscience. But Steffen will talk a lot about what we always talk about, this magical group down in Australia that's been there for 20 years. He started it back in, around 2007, and it's been this team that's continuously honed their ability to make differentiated antibodies. I know we talk about everyone can make an antibody. They can't make an antibody like Teva, and Steffen will walk you through why we see that and what extra measures we put into it. But we've proven ourselves on TL1A, and you're seeing how we've proven ourselves with anti-IL-15. You'll hear about TL1A/IL-23 today for the first time.

We'll talk a little bit about TSLP/IL-13, and we'll also highlight some new clinical data on PD-1/IL-2. These are all the results of, I would use the word again, relentless obsession. Sometimes they take a little too long to do it, but the product at the end of the day is completely differentiated from the very beginning. I'll highlight it now, that one of the things that we always strive for and aspire to in drug development is making a molecule at the bench side, thinking about how it's going to fit into a commercial market in the future. That's the ideal. Very few times does that happen. Usually commercial shows up when phase III is finishing, and that's when we've already handed the ball off. It's either going to be good or bad.

If you think about where the market is when you're thinking about a molecule, that makes a really great runway to success. I'm really proud that Steffen will be talking about that today. Then finally, I'll talk about the last point I want to make about how we think about R&D and differentiated our thinking and our strategy, and that's about how we execute rapidly. A little under four years ago, Richard showed that first slide, and we looked at the pipeline that was there. It was a forgotten pipeline, but we leaned into it. WELTRUZA, the magic of 505(b)(2). We skipped phase II. We went right from phase I - phase III, and that's a fantastic product. I'm really excited to see how that does in the market. That's going to help a lot of people, I think.

Anti-IL-15, we took 18 months off that program by just doing a phase II/III study design. These are simple things, but people don't execute them. You have to get rid of the white space between studies and seamless designs. You know when you can push the envelope and when you can partner with a health authority to get that done. Ecopipam, one of the newest things we've got on the list. We knocked off four months with the early priority review, which is fantastic. Even at that late stage of a program, we're still speeding it up. Then finally, AUSTEDO XR. The XR, we didn't even run a study for that. That was a PK modeling and simulation on a complex formulation. No study.

That's almost a year and a half at least that we took off of that, and that's really driving value with the titration pack and the once-a-day dosing. Very proud of the team who did that. We think about the way drug development is done. David and the team, we know from our past experience how you can do this and how you can partner and move programs forward. One of the other things we're super proud about is how we've used deals and partnerships to make everything possible. As we said, we're agnostic to where innovation comes from. Emalex and BioXcel brought in ecopipam and dexmedetomidine. We've also now partnered with other groups like MedinCell and Biolojic Design to bring in expertise, formulation expertise, AI, to expertise for designing antibodies, and finally, Sanofi for expertise, but also bandwidth, because we knew duvakitug is going to be big.

We need bandwidth to really execute on a large program. The last thing I'd also bring up is Blackstone, Royalty Pharma, and Abingworth. These were some of the real driving energy engines where, when we see something good, we just start working on it, and we figure out how we're going to fund it later, whether it's going to be reallocation of capital within the company, or we have an external partner come in and do a really good due diligence, and when they agree with us, we run as quickly as possible. It's the combination of these ways in which we approach the partnerships that have accelerated all the development in many different ways. They all have their own piece to the puzzle. Very proud of them. Never have done that many deals and helped a program move that quickly. 2026 was a good year.

We started the year out with this list of This was our to-do list for 2026, and I'm very proud that we basically have checked all the boxes. You'll hear about data from PD-1/IL-2 today. I think the capstone on this slide was the WELTRUZA approval, and we're looking forward to the last exacerbation in the DARI program by the end of the year. Really great execution. It's been a busy year, and the team at Teva has done a fantastic job on sticking to this, doing what we say and saying what we do. But we did more. We did more than that list. Other things fell out of the sky. We got ecopipam deal in with a filing to the FDA. We got the dexmedetomidine. It's submitted, and we're waiting for that PDUFA date soon.

We're also interrogating and starting all these other studies and other programs, new products, new studies, expanding the portfolio and the indications that we have. We overachieved when it came to our milestones. But 2027, it's going to be another year. We're going to have a number of milestones. You guys got to get used to this slide. We're going to be talking about this all next year, starting with hopefully the approval of ecopipam in the first half, the top-line results from DARI, and then the DARI submission next year, and then these other study starts and milestones for the earlier pipeline. A lot coming, more catalysts. We're very excited to really start executing again for the next year.

So, let me kind of bring it up, and I will give you an example of why I can tell you our mindset has changed and really accelerated the way we do work at Teva. We focus on unmet medical need, patient impact, using proven science. We always have a differentiated product. That is a must in all our programs. Finally, we use all our know-how, savvy, and experience to make sure that we move that through the clinic as fast as possible. Sometimes it is very simple. It is not something that you stumble through. It is something you have the vision to do. I will end with this. I will give you one little caveat or story that David will probably tell you a little bit more about. As an example of how we think, I love talking about the anti-IL-15 program.

The reason for that is, we were going full bore in celiac, and we still are. We had two proof-of-concept studies in celiac, and it was generating great data, great safety data. We had great phase I work. We also were running a vitiligo study at the same time and a proof of concept. I always told this team, "I do not care about any of the biomarkers. I just want to make sure if people's skin change color, that will be important." To the credit of the team, the first two patients, and David will show them, their skin changed color. I am not kidding you, within two weeks, we completely pivoted. We accelerated vitiligo. We went to the FDA, got their buy-in. We got funding from our partners at Royalty Pharma.

Before you guys ever saw the data, we were already going into the phase II/III seamless design. That, I have never seen at another company that I have been at. That mindset of seeing data but then acting on it, without even knowing how you are going to get there, is how we really executed. I am very proud of that team and how hard they have worked on it. I just want to introduce now Steffen Nock and David Gardiner. I am going to say a little bit about Steffen first. I mentioned, he has been at Teva for at least 20 years. The fun thing about Steffen is he started a business many years ago, a company that then merged with another and then became part of Teva 20 years ago. It is the same group down in Australia. We kid that they are hiding down in Sydney.

They have built up institutional knowledge where their perfectionist attitude about developing antibodies, not in the same old ways, but in new ways every year, has been a real benefit to Teva. After Steffen, we will hand it off to David Gardiner. I have known David Gardiner for about 15 years. I mentioned before that we both cut our teeth in the hepatitis C days. Those hepatitis C days, anyone who lived through it learned about speed. Hep C world changed every three months, and you had to figure out how to pivot constantly in that field, both in a regulatory way, in a scientific way, in an execution way, in clinical studies. His expertise, you can see, bakes into the way we think about all our programs at Teva. With that, thank you very much, and I am going to pass it off to Steffen.

Steffen Nock
Chief Scientific Officer, Teva Pharmaceutical Industries

Thank you so much, Eric, and welcome, everyone. Today, it's a big pleasure here to talk about our early next-generation high-value assets. I think the strategy is very clear. Eric talked about it. It's about the patient first, what is the unmet medical need, and then we are applying a combination of a deep understanding of disease biology with precision antibody engineering. Me, as you can hear, being German, I love engineering. We choose our target based on proven science, which should increase the probability of success clinically, but also commercially. We leverage precision antibody engineering across multiple formats. We're going way beyond the classical monoclonal antibody. We're talking about bispecifics, we're talking about a super exciting molecule, which is a dual-specific, it's the only one in the industry I really know, and cytokine engineering.

Another key advantage is that we are focusing, like Richard said, we're focusing on multiple indication, the pipeline and the product. This is very important, and you will see all of our molecules have that potential. As a result, we are creating a high-value pipeline with a very high probability of success. Let's focus on this pipeline, and it's really a nice illustration how the productivity of a well-oiled antibody engineering capability can lead into a very differentiated pipeline. You have heard about TL1A and anti-IL-15. You will hear more about from David about the clinical data. These are two molecules which were developed in-house with the idea of being clearly differentiated and having best-in-class potential. They are now in late-stage clinical trial, TL1A, mid-stage clinical trial for anti-IL-15, and again, they are tested in multiple indications.

Now we're using our engineering capabilities, like Eric said, has been evolved over 20 years to come up with next-generation molecules. What you're going to hear today about is our TL1A/IL-23 bispecific antibody, and hopefully I can convey to you that this is differentiated antibody. The next one is, I'm super excited about, TSLP/IL-13 dual-specific antibody, AI-engineered, and we're going to spend some time on that to clearly differentiate it versus bispecific ones. Again, asthma is a primary indication, but there are other indications where Th2 biology plays a big role coming behind. Then last but not least, we used precision engineering of cytokines to come up with our PD-1/IL-2 molecule, which selectively can activate tumor-reactive T cells. Hopefully in the next 15 minutes, I can convince you that these three assets really are highly differentiated and have best-in-class potential. Let's focus on TL1A and bispecifics.

We have the luxury, we can build on a very well-validated backbone, namely duvakitug, potentially best-in-class molecule. We take this as a basis to come up with our bispecific portfolio. We start with a potentially best-in-class duvakitug arm, and if you look at the biology of TL1A, it's not just a cytokine activating one pathway. It's really an immune amplifier. It plays a role in innate immunity and adaptive immunity, and also in fibrosis and tissue remodeling. It's a perfect partner to combine it with other molecules. What we are doing right now, we're combining it with validated biology, meaning that we really try to build up a synergistic effect by having two cytokines blocked at the same time. We have a very active TL1A bispecific program. The question is, what should we pair it first? The answer is IL-23.

Eric took that already away from me. We are going to focus first on our anti-TL1A/IL-23 antibody as a bispecific one. The reason for that is both targets are validated in IBD. IL-23, we have approved antibodies, we understand the biology. TL1A, getting more and more validated with several antibodies in clinical trials. Let us have a look at the design and hopefully the differentiated design of our TL1A bispecific. Like I said before, it is derived from duvakitug. It blocks both pro-inflammatory and pro-fibrotic pathways, and as we said, it is an emerging pathway in IBD. On the other hand, you have the IL-23, which is more downstream and blocking basic or activating Th17 cells. By blocking that, you really compensate for Th17 biology, preventing the secretion of pro-inflammatory cytokines such as IL-22, 17, interferon gamma. But we have done more than just having a bispecific antibody.

We have first of all extended it for half-life. The second trick we applied to is a pH tuning. Not a lot of people have done pH tuning of an antibody before, and this allows us to clear the target very efficiently out of the circulation. I am going to illustrate in a slide or two how that actually works. Both pathways are key mediator of IBD mediators, and we have it formulated, so we have very convenient subcu administration. It looks almost like a normal antibody. Why TL1A and IL-23? Well, TL1A, like I mentioned before, is made by fibroblast endothelial cells, monocyte dendritic cells, and it is not a typical cytokine. It really amplifies pathways. So it has involved in fibrosis by working on keratinocytes and stromal cells, but it also has Th2 and non-Th2 biology.

On the other hand, we have IL-23, which is really a driver for the maintenance and activation of Th17 cells, which is a non-Th2. While these pathways look interconnected, they are not identical. So by blocking both, we are expecting a synergistic effect, and therefore, a better suppression of the inflammatory cascades in these patients. So let me now focus on what is really making this antibody differentiated. It is really the pH tuning of our duvakitug arm. As you might know, antibodies circle in the blood and get recycled all the time. You can apply one trick, which is a YTE everyone is doing in order to increase the half-life. We do that, but we go one step further, and we make the binding of the target TL1A pH dependent. The reason why we are doing that is we know how an antibody is recycled.

I have a little animation showing that. For instance, in the blood, you have your antibody TL1A complex. It gets taken up by pinocytosis, forms an early endosome, and if you compare now the pH of the blood, which is physiologically 7.4, and what is happening in the endosome, in the endosome, the pH drops to about pH 6, and then things start to sort. The YTE makes sure the antibody binds to the recycling receptor under pH 6, while the pH tuning makes sure that the target gets dissociated under pH 6. We are separating the antibody membrane bound from the target, and what is happening then is the sorting endosome is going on one hand with a soluble fraction into a lysosome, where the antibody gets degraded by peptidases very quickly, versus in the recycling endosome, we bring our antibody back into the circulation.

We are removing the target not by binding to and blocking it. It is really an active degradation of the target, which should give us better disease control because we are taking it really out of the equation. We have a half-life extended pH-tuned antibody. Now you ask me the question, "Show me it works. Can you really make an antibody pH tuned?" That is shown here in this slide. It is just a simple experiment where we present TL1A on a chip, and then we take the antibody, which is not pH tuned, let it bind.

You see it binds very quickly. Same for the pH-tuned antibody under pH 7.4, but then we shift the pH down to six, and what you can see here, the non-pH-tuned antibody slowly dissociates from the complex. We are talking about a 10-minute window, which is relevant for the recycling mechanism I just illustrated.

However, our pH-tuned duvakitug, you can see it is a very quick release of the target in the timeframe which is relevant, and therefore, we have about a 95% increase in target dissociation. It is really working. In summary, I think we have an antibody now which is long half-life, pH tuned, built on duvakitug, it is engineered for low immunogenicity, it is engineered for good manufacturability, and we have a subcu administration. That is a differentiated molecule we bring it forward very quickly. Let us shift gears. Now I am going to be excited because this is a dual-specific antibody. It is an AI-designed antibody where both arms can bind to two targets. You would not be able to do this in a mouse.

If you inject the mouse with a TSLP and an IL-13 and hope you get an immune response, you get it, but versus one or the other, but not an antibody which can bind at the same time. Look at the structure of the antibody. For those who are familiar with antibody structures, it looks like a normal antibody. Well, it is a normal antibody because we have two identical heavy and two identical light chains. No domain swapping or anything. It is a plain vanilla antibody. It is engineered to bind with both arms, basically TSLP, which we talked, which is an upstream alarm and blocks the initial inflammatory cascade, and then can also bind to IL-13, which is downstream affected cytokine, mostly driving Th2 biology. We are combining, again, two validated targets to get better neutralization.

The dual-specific binding, which I will show you on the next slide how it works, can block both cytokines at a time. Again, we have it engineered for low immunogenicity, good manufacturability, looks like a normal antibody, behaves like a normal antibody, and extended half-life. Let me show you the principle and the differentiation between a dual-specific antibody versus a bispecific antibody. It is fundamentally different. This molecule was designed by AI with our partners at Biolojic Design. What you can see here, it is almost like a smart antibody. It knows what the concentration of your target looks like. For instance, in the airway epithelium in asthmatic patients, we typically have mostly a TSLP because it is upstream, it is an alarm, and it triggers the immune cascades. The antibody senses that. It now can bind with both arms against the same target, TSLP.

If you then go and change the environment, and we look at the draining lymph nodes, where you typically get more Th2 responses and IL-13 in the circulation, the antibody is smart and can bind now with both arms to IL-13 and take it out of the equation. If you go to a different compartment in the patient, like a mucosal space, where we have both cytokines, maybe in equal concentration, the antibody is potent enough so that one arm can bind TSLP, the other one can bind IL-13. So it is a very smart antibody. Does it matter? Yes, it matters, in particular because we have the dual blockade. This is a simple experiment where we took PBMCs, we stimulated them with both TSLP and IL-13, and then we looked at the activation of Th2, and a marker for that is CCL17.

If you activate now these PBMCs and you block them with commercial antibodies against TSLP or IL-13, we get about a 70%-75% blockage. If you use our antibody, we get 100% blockage of the Th2 response. So that should lead into profoundly better potency once administrated to patients. Summarizing, it is, to my knowledge, one of the first dual-specific antibodies engineered for long half-life, engineered for low immunogenicity, engineered for good manufacturability, and our convenient subcu administration. The last program, which is a bit different, it is our PD-1/IL-2. Here, we did not do antibody engineering. Here, we did cytokine engineering. The reason why we are doing that is IL-2 is a very potent stimulator of the immune system. It is approved for several cancers, including renal cell carcinoma, melanoma.

As you might know, IL-2 is very toxic because it stimulates the immune system, and often you cannot give it at high enough concentrations to really see a profound anti-tumor effect because the side effects are not tolerable. You have cytokine storm, nonspecific activation of your immune system. However, if you are lucky and you get a response, the response is very durable. So IL-2 is a good molecule. The therapeutic window just is too small. What we did is we applied, smart engineering. You can see what molecule we came up with here. It is a PD-1 antibody, normal PD-1 antibody, and then we have an attenuated IL-2 fused genetically to the back end of the antibody. What does it mean? On the PD-1 side, it can bind to any kind of PD-1 expressing cells with high affinity.

The PD-1 was designed to be non-antagonistic, non-agonistic, and more importantly, we also designed it that we do not block the binding of standard of care, like KEYTRUDA and OPDIVO. So we can basically add it as an add-on therapy. On the other hand, we have the IL-2, and we engineered it to have a lower affinity to the receptor, and lower meaning 1,000, 10,000-fold lower. So what it means is it cannot bind to the receptor unless you use a trick by having the hook basically with the PD-1. So we have fusion protein, fairly easy to manufacture. We engineered it for low effector function. We do not want to non-specifically activate the immune system. It is very potent in preclinical studies. More excitingly, we have some phase I data I am going to show with you in a second. How does the principle of ATTENUKINE work?

Like I said before, IL-2, very pro-inflammatory cytokine, binds to all kinds of cells you do not want to activate, such as endothelial cells to get the vascular leak syndrome and cytokine storms. If you apply that to the body, you get a nonspecific activation of all kinds of IL-2 receptor expressing T cells. If you then fuse an attenuated version to a targeting antibody like PD-1, again, if the IL-2 encounters the receptor, being now so attenuated, it will not bind because the affinity is too low. However, if you find a cell which expresses PD-1, like a tumor-reactive T cell, also expressing the IL-2 receptor, you get a cis reaction. You get a high local concentration.

Basically, PD-1 is the hook to bring your cytokine to the right target cell, and you get activation of tumor-specific T cells, and not the off-target effect like we see with plain vanilla IL-2. It broadens the therapeutic window. That is the concept behind it. We have broadened basically the therapeutic window of IL-2 therapy. Does this translate into any meaningful anti-tumor effect? It is shown here in an animal model. This is syngeneic mouse model where we take a mouse tumor, in this case was a colorectal cancer cell, we graft it into the mouse, and then we take two different antibodies, one of which is a blocking PD-1 antibody ATTENUKINE, the other one is a non-blocking PD-1/IL-2 ATTENUKINE. Remember, I said we do not want to block the standard of care, the OPDIVO, KEYTRUDA. You can see here, we have the established tumor.

If you treat with vehicle, the tumor grows. Nothing happens in regards to being tumor suppressive. Both antibodies, ATTENUKINEs, block tumor progression and even cure the mice basically. That is very nice, but more importantly is the experiment on the right-hand side here, where we take these cured mice and we try to re-establish a tumor. We cannot. We have a profound memory effect, which should translate into a more durable response. It is a very nice illustration how we have engineered our cytokine, taking a PD-1 hook in order to be very efficacious, at least in a mouse model. This is the most exciting slide here. Now we are talking about patients. What we did is we started our phase I study. It was a normal phase I dose escalation. We had to start at very low doses because of known toxicity of IL-2.

We used it as monotherapy. Remember, I said ultimately you can add it on to KEYTRUDA and OPDIVO. We dosed every two weeks. The patient population we chose was, all of them had advanced cancer, median treatment cycles were four different therapies, and they were all refractory to PD-1, so they did not respond to PD-1 anymore. We tested 11 tumor types, including renal cell carcinoma and melanoma. So far, what we have seen today, having been now at a dose level, we have a very favorable safety profile. We do not see the toxicity we would expect by having just pure IL-2 given to these patients. On the other hand, it is very exciting to see on the right-hand side, the first readout of 25 patients, the study is still ongoing, and we are talking mostly about the lower doses where we have data for.

You can see the minority of patients progress on treatment. The majority has stable disease. Very encouragingly, keep in mind it's a monotherapy, we see a response in target lesion reduction. We have one complete response and six partial responses so far. Like I said, we are talking about the lower doses. This is very nice and promising data set for our precision-engineered anti-PD-1 IL-2 cytokine. I would like to finish by bringing this all together. Why does it matter? Why are we differentiated? We talked about the TL1A/IL-23 with enhanced target clearing using the pH tuning, long half-life, subcu administration, and built on duvakitug with our low immunogenicity profile. We have our exciting dual-specific antibody, which is precision-engineered, AI-created, with an extended half-life and allow for a subcu administration. Again, coming back to what Richard said, multi-indication potential, pipeline in the product.

Last but not least, the PD-1/IL-2, with very encouraging preliminary early safety, no safety signal and efficacy data. It only activates the PD-1 expressing tumor-reactive T cells, and it can be combined with standard of care. You do have to think a bit more than it's not just KEYTRUDA or OPDIVO. There's a lot of bispecific PD-1 antibodies coming out there, the VEGF bispecifics, so you could add it onto those too. This is my last slide. I just want to give you a little tease of what's coming along. We talked about the first three programs, but before I do that, I would really like to emphasize, like Eric said, we have this team in Sydney, which I work now for 20 years. What we have done is we have perfectionized antibody engineering over all this time. We have adapted the early hybridoma technology.

We went to the single B cell technology. We're using AI right now to really think about how can we come up with the most simple but differentiated antibody. I have to give Richard and his team credit, because when they came in and started the Pivot to Growth strategy less than four years ago, they really gave us enough attention to move this project forward. We got the right funding, and as a result, you see we have a duvakitug with an IL-15. We have a pipeline coming behind. You can see here, I have seven more on the list. I can't talk about them today, but these are all highly engineered bispecific, trispecific, bifunctional antibodies in diseases such as AD and any kind of inflammatory diseases.

The other thing you have to keep in mind, once you have optimized a binder, such as a pH-tuned TL1A, you can think about the LEGO principle. You can take that arm in combination with another arm and so forth. You can come up with smart combination targeting multiple cytokines at once. With that, I'm going to hand over to David, who's going to talk more about the clinical stage and how he's going to push it at very high velocity towards approval. Thank you very much.

David Gardiner
SVP and Head of Innovative Medicines and Clinical Development, Teva Pharmaceutical Industries

Thank you very much, Steffen. I'm David Gardiner, and I lead our innovative medicines and clinical development groups here at Teva. I've been with the company for about nine months, and I couldn't be more excited to be with this fantastic team. I want, throughout my presentation, to sprinkle in a little bit of that excitement and the reasons why. Maybe I'll start with just a reflection, that Teva is a company of ambition and growth unlike any of the companies that I've had the privilege of working for. Together with Richard and the team, we are empowered to set ambitious, I'd say audacious goals.

Everyone from the leadership team down through the development, commercial, manufacturing teams all get behind to make one simple statement, and that's, "Let's find a way." On the scientific side, I'm going to take that exciting innovation that you heard from Steffen, and I'm going to tell you how we pull it through and marry it with proven science to deliver it with urgency and speed to patients who need these innovative and transformational medicines. Let's start with our own homegrown anti-IL-15, again, coming out of our discovery group with Steffen. IL-15, it's a cytokine that we are learning is driving skin disease and gastrointestinal disease. These are conditions such as vitiligo, alopecia, celiac disease, and these are all core competencies for Teva. Let's start with vitiligo, our most advanced indication. The issue with vitiligo is that it is visible every day.

Think about the impact that this depigmentation has on the patient. It impacts decisions that we might not even think about. Do I want to wear that short-sleeved shirt today? Do I want to go to the beach? Do I feel comfortable in the bathing suit? Even, do I want to take that job where I might have a very social-facing role to play, and am I comfortable with the changes that are happening to me? Unfortunately, the therapies that are available, the topical JAK inhibitors, not appropriate for patients with extensive disease, and the oral JAK inhibitors, for example, are going to come with some pretty important safety warnings that patients are going to have to weigh. On the science side, it's very clear that IL-15 is a driving disease. It's driving those T cells to attack the melanocytes and cause the depigmentation.

This is where we believe that anti-IL-15 can be fundamentally, has the potential to be disease-modifying in a way that other developing therapies may not be. Eric referenced this. This is the pictures that changed the world for us, hopefully for patients, two patients from our clinical trial in vitiligo, before and after, as you move from left to right. In the patient's own words, these findings were dramatic, very much improved, was how they described it. I want to emphasize also that this transformation was delivered with just two well-tolerated doses that were delivered subcutaneously quarterly. That is a very profound profile to consider for a patient. I'm very excited to share with you our high-velocity biopharma approach to our pivotal trials.

We're taking two trials, combining them into a single protocol in vitiligo, and we're going to use the 24-week data from trial one to inform and educate trial two, which will start at risk. This is accelerating the program by years. We're now looking at a U.S. filing in 2031, and we're actively pursuing further indications because we know patients don't want to wait for this kind of innovation. Let me follow vitiligo. It's the perfect time to then dovetail into alopecia. I want to impress upon you similarly that alopecia is not just hair loss. Think about your own hair. Maybe think about the hair of your children, maybe your aging parents. Hair is a manifestation of how we want to present ourselves to the world. It can be a reflection of our personality. Perhaps we even think about our values.

The loss of it has a profound effect on our self-confidence, how we want to relate with other people, how comfortable we are. Unfortunately, current treatments are either unreliable, they're not adequate, or they're going to come with significant safety warnings, as I mentioned in the case of the oral JAK inhibitors. Again, you can see the similarities between vitiligo and alopecia. There's a rhythm to the similarities across science and the medicine. IL-15, again, is driving those T cells to attack the hair follicles. In the same way, blockade may, in fact, be disease-modifying for patients. We believe this might set this therapy apart. Here are some new results from an animal model done inside of Teva, where we take skin grafts with hair into an animal model.

We give those animals either anti-IL-15 or placebo, and the anti-IL-15 was able to prevent the hair loss. This is a good sign. I would argue the more important lessons are actually coming from our clinical trials in vitiligo. Why do I say that? Because there's some fundamental principles that we've learned. First, we learn that the anti-IL-15 gets to the target tissue. We also know what doses and exposures are adequate to inhibit the T-cell activity and deliver a clinical result. These are all parallels that are critically important and fundamentals to drug development, and we believe we see them here. Perhaps no other indication is so primed for a high-velocity biopharma approach, and we believe we can drive this indication very rapidly into late-phase development. Now I'm going to move to celiac disease.

One thing I would love for you to come away with today is the understanding that gluten sensitivity is not just an inconvenience. It's not just, "Oh, I got to try to avoid gluten during my day." This disease causes real symptoms, abdominal pain, diarrhea, can lead to infertility, and is even associated with certain types of cancers. Once again, IL-15 is driving, recruiting, activating those T cells to move into the gut tissue, to take those healthy villi that rise up into the lumen of your bowel and to kill them, and to lead to a diseased gut. Now, I'm going to take some time on this slide, because this slide, perhaps unlike any other that you're going to see, really gets me excited. It's one of the joys of being in this industry where you get to see just a unique kind of data.

I remember when I got the call about this study result and was at the privilege of seeing it. Very few times in my career do you see the primary endpoint, all the secondaries, and all the biomarkers all going in the same direction. I got to call Eric. I was like, "Eric, we got something here. You're really going to like this. You're going to be happy." He was. What did we do? We took patients with celiac disease. They had to be controlled on symptoms. They had to have healthy gut biopsies. We exposed them to what amount to a slice of bread every day for six weeks. I want you to digest that for a minute, no pun intended. What does that tell you about how important this disease is to these patients?

These patients know that by doing this, they are not going to potentially feel well. They have no idea that anti-IL-15 is going to help. They have no idea if they're going to get placebo. But they're willing to put themselves in harm's way for six weeks with the promise that they might be able to move the needle and have a future therapy someday. If nothing else tells you today how impactful this disease can be, when I reflect on that study, I think about that gluten challenge, what it means for the patients and their willingness. I can't thank those families and those patients enough, as we all need to do in development. What did we see? You can see on the left side that anti-IL-15 with a single dose was able to prevent that loss of villus height.

On the right side, you can see the T-cell markers, whether it's T-cell infiltration, proliferation markers, et cetera, were all just dramatically improved with a single dose of anti-IL-15. Most importantly, these results correlated with better symptoms. As we advance our program in that high-velocity biopharma fashion, we're taking that exciting data, and we're combining it with FDA fast track. We're negotiating with the regulators now. We're working very closely with experts. We're going to be down in Australia in the celiac meeting, I believe, next week. We are going to, once we have endpoints agreed upon, we're going to be launching a new study second half of next year that's actually going to look at both prevention of symptoms, like I just talked to you about, as well as gut healing in individuals with ongoing inflammation.

With endpoints agreed, we can move rapidly into phase III development. Let's stay in the GI tract, and I'm going to move to our potentially best-in-class antibody, duvakitug. I want to take a little aside. Every once in a while, all of us, you with perhaps the drug development community and scientists and physicians, we get to witness a paradigm change in disease. This often comes from those special times when clinical science proves a basic science principle in a way that changes the way a disease is viewed and treated. I believe that many of the diseases I'll talk about in the coming slides, inflammatory bowel disease and others, are having just such a renaissance with TL1A. With TL1A and inflammatory bowel diseases, we know that there's been a plethora of treatments that have come out in recent years.

Unfortunately, many of these patients are not achieving the remissions that they need, and new therapies are required. So enter duvakitug. Here, we have some of the results that have really just galvanized ourselves as a company behind this future medicine. You can see the remission rates for both ulcerative colitis and Crohn's disease from phase II. Underneath these overall remission rates are really industry-leading results in terms of induction as well as maintenance rates. I want to also emphasize, these results don't happen by accident. They come from a unique marriage within Teva where we're able to work with our commercial colleagues, medical affairs, to understand what's the need first, get it done in a rapid execution in R&D. But within Steffen's group in discovery, it's a focus on the basics. Do you have the best affinity? Do you have the best engineering?

Have you removed the immunogenicity so that you have low anti-drug antibodies, such as duvakitug? You're having a lack of immunogenicity and an outstanding safety profile. This starts with the basics, because in the clinic, you can never make up for the things you didn't think about in the lab. Now I want to take a little diversion, and we're going to talk about a very underappreciated complication of the inflammatory bowel diseases, and that is stenosis. You might be surprised that up to 50% of patients with ulcerative colitis, especially Crohn's disease, will suffer a stenotic complication sometime during their disease, and there are currently no medical therapies. But what is stenosis? Quite simply, it's a narrowing of your intestinal tract or your colon so that the foodstuffs can't move through.

In the worst case, this creates a medical emergency that requires surgery or dilatation with an endoscope, even removal of sections of your intestine, and there's no medicine that can make this better. Part of the issue is that the available therapies focus on inflammation, but that's only part of the story, as Eric and Steffen had talked about. The TL1A pathway and duvakitug as a future medicine offer the promise of addressing both the inflammatory pathway, but also modifying the fibrotic pathway, again offering best-in-class profile with the potential for disease modification in a way that the currently available therapies do not. We are leaning into this.

What I see before you is a groundbreaking study that will start, it's actually in study startup now, and we're going to look at how 24 weeks of duvakitug in patients with Crohn's disease and defined stenosis can reduce and shrink those stenoses. With success in this study, we could lay the groundwork for really a revolutionary way to prevent this devastating complication. I'm going to wrap up duvakitug, focusing now on the skin and hidradenitis suppurativa. This is a disease whose prevalence is increasing. I believe the market is projected to close to double in the next 10 years, and unfortunately, half of those patients are not going to see a response from the currently available therapies.

Now we know, as I have explained in some of those other diseases, that TL1A has a central role in taking normal skin and moving it to a diseased and damaged organ. What does this mean for patients? Those are very generic words. On the right side, you see what this means for patients. Scarring, pus drainage, pain, and perhaps worst of all, a pungent odor from the bacterial overgrowth in this damaged skin that is with you all the time when this disease is not under control. It is hard to conceive of how uncomfortable and self-conscious you would be if everyone around you could know this and smell this. Once again, TL1A again is driving disease both through inflammation and fibrosis, and we have the potential for disease modification by inhibiting the fibrotic components of this disease.

Also excited that we now have our first patient enrolled in our hidradenitis suppurativa trial, and in high-velocity biopharma fashion, we are going to take that 16-week result and we are going to combine it with what the field knows in hidradenitis suppurativa, move very quickly into pivotal trials. I would like to conclude with our DARI program, our dual-action rescue inhaler for the inflammatory condition of asthma. I would be remiss without telling you my disappointment that we have known asthma for decades. We know that the combination of an inhaled corticosteroid plus a short-acting beta agonist is the best therapy and leads to better outcomes. My disappointment stems from not that we know that, but that most patients in 2026 are not getting it.

This might contribute to the thousands of patients in the U.S. that still die at this time from asthma, which is a ridiculous statement to have to make. Part of the reason is delivering these medicines is not convenient. Our DARI program is an example of pulling commercial and medical know-how, insights into what a patient needs to build a better inhaler, and the RespiClick device is going to deliver true open, inhale, close convenience for a patient. None of the mixing, shaking, and worst of all, with the currently available devices, if you do not time that inhalation to the medicine, you do not get the medicine. All that effort is for nothing. All of that goes away with the RespiClick device, and we are very excited that this could really, through convenience and knowing what a patient needs, lead to better outcomes.

I want to conclude with our exciting news that our phase III program is now fully enrolled. This is a great example of our ability to execute at scale in difficult diseases and do so with speed and quality. We are on track for a submission in the second half of 2027. Let me return now to the beginning. I hope I have provided some compelling evidence that this is a company that is realizing its Pivot to Growth strategy through comments on anti-IL-15 and duvakitug, that we have a gritty culture that is taking this innovative research, combining it with the best science, and executing to deliver for patients best-in-class potential medicines with portfolio and a product aspirations.

Our DARI program is a great example of looking around corners to see what a patient really needs and then working with other competencies and devices and formulation delivery routes where we can really change medicine for the better. I have to tell you, developing medicines, being a part of a team like this is one of the joys of my life. What might be even more joyful is when we deliver those medicines and we hear the appreciation from patients and practitioners and to see what a very talented group of commercial leaders and teams can do when those medicines get out into the marketplace. Please, we're going to take a 15-minute break and join me back. I'll pass the baton to my commercial colleague, Executive Vice President Chris Fox, Global Commercial. Thank you.

Operator

Please take your seats. Our program will resume shortly. Please take your seats. Our program will resume shortly. Please take your seats. Our program will resume shortly.

Speaker 7

[Presentation]

[Presentation]

[Presentation]

[Presentation]

[Presentation

[Presentation]

[Presentation]

[Presentation]

Chris Fox
EVP, Teva Pharmaceutical Industries

I wanted to start with this video because I find it super humbling. It is a big part of our ethos on the commercial team to think about the patient, and it is our pleasure to be able to share some of their stories with you so that you can feel what we feel and have an appreciation for how important we think the work is of translating the great science to making it meaningful in patients' lives. Good afternoon, everyone. Great to see you. I am Chris Fox, and I am going to aim to do a couple of things today, and the first is take the great presentations that you heard today, and thank you guys. Awesome job. It is incredibly motivating to hear the work behind the work. We get it much further down the pike, and we really, really appreciate that.

I am going to aim to give kind of some context of how do we think about it commercially. Fundamentally, there is a couple things that has already come out that we have this really beautiful handoff where we work hand in glove. Eric's team and my team, we are always thinking about from the patient journey perspective, what really is the unmet need? I am going to talk a lot about that in the next couple of slides and some of the products I will cover. We also loop in BD in that kind of triad, and that is very purposeful as well, because we have to think about what are some things based on the capabilities we have built in commercial or our science know-how that we can add products, and sometimes they are a plug and play. We will talk about a couple of those today.

And some of those are more larger constructs where we think about where do we want to go and how do we want to build on what we see as the evolving opportunities in commercial. That's one part. This notion that we're rooted in the patient journey, you can see from our R&D team that they're obsessive with this. I'd say so are we from a commercial perspective, because to get patients and even physicians to change their behaviors, you have to really deeply understand from where they're coming from and that base case. Then this idea of, okay, we know all of this stuff, but how do we apply it and how do we make it real in a very, very complicated world where there's lots of interference with access and just getting medicines to patients that need them?

Then lastly, I'm going to sprinkle in a little bit of what we call our secret sauce, because it is special. I think we take what we do very, very seriously. I'll do my best to try to give you some perspective on kind of how that happens and how do we unlock the path to value. I showed this slide the last time I stood before many of you that were in the room at our Capital Markets Day. I love this slide because this really, really shows and demonstrates some of the things that I think are a part of the things that we do really well, and that's talking about the patient journey.

It's particularly relevant now with the launch of WELTRUZA, but also because we have continued learning throughout this space post the launch of UZEDY, kind of reframing that opportunity and now applying it in a totally different way with WELTRUZA. There's a couple of things that are important to understand and appreciate about this patient population aside from kind of what you heard from the video. The first is that typical patient in schizophrenia onset is in their teens. They're misdiagnosed for a very long time. They get diagnosed with depression, anxiety, and on average, it takes about 8.5 years from that first onset of symptoms for them to know what their diagnosis is. So imagine living like these folks on the video and not really knowing what's causing all of these problems, significant problems in your life.

Then they start treatment, and usually they start with an oral. Oftentimes what we see, and you guys will see this from the data that you look at, that they'll cycle through many orals, sometimes because it's not efficacious enough or they have side effects and they can't quite find the right one. Ultimately, if they're lucky, they end up on an LAI, a long-acting injectable, but sadly, it's usually because they've relapsed, which is a bad reason to start a new medication. It's almost out of necessity. That's where we make a really, really big difference, because we appreciate that LAI is really helping them say that inadequate control has significant consequences. That's what this slide really demonstrates, that relapses absolutely increase illness severity. There's 100% correlation with that. Most patients, about 80% of them, relapse multiple times in five years.

When we unpack the data a little bit more, what we see is that when treatment's interrupted, so they're taking something oral, LAI, whatever it is, when that's interrupted, 77% of the time, they have a relapse in year one. 90% of the time when they have an interrupted treatment protocol, they relapse in year two. When a patient's consistent, a la an LAI, they only have relapse about 3% of the time. What you'll see in this data and others is that relapses dictate other relapses. It becomes kind of a kindling effect, that they have this worsening cognitive disability, and it really ultimately starts to address and deteriorate the gray matter in their brain. Obviously, that's something that we want to try to avoid, and that's the clinical consequences.

It also affects massive things in their life, from independence, can they hold a job, are they ending up homeless, does it rock their life so much that they end up doing something and end up being incarcerated? The consequences to this are massively severe. It's clear, patients need consistent treatment, no matter what that treatment is, over time. This is where we come in, and we're really, really proud of this. Again, Eric, you and your team have done an amazing job. We couldn't be happier to be having WELTRUZA and having that launch in our capable hands. It is our second LAI, so it expands our leadership in this space, and now we have a franchise. It's such a great example of Teva innovation in hand.

It's the first and only monthly subcu LAI with proven olanzapine efficacy, and that's really, really important because there's a very knowing quality of olanzapine. Physicians know this, and they count on it to be the most efficacious oral. This image is kind of striking, and it was a little shocking when we first tested it, and our team was like, "Gosh, it's pretty out there. It's not your typical pharma ad with a dog and a child, and everybody's walking hand in hand." It was really purposeful because we wanted people to stop and take notice, and so we thought, "Okay, well, let's test it with patients. How do they feel about it?" We said, "How do you feel about your disease?" You got a little snippet here in the video. They said, "Gosh, we feel really knocked down."

We feel tired." On average, the folks that we talked to had three hospitalizations, and so they were like, "We want something different. Make us feel like we can get control of our life back again." We showed them this image, and their responses were, "Gosh, she looks like someone that's picked herself back up. She's got a comeback. She's reinventing herself. She looks ready for powerful therapy." They said, "This connotes to us resilience, renewal, and the promise for a better tomorrow." We were like, "Well, that's our campaign. Let's do this." Because we needed to give them that power back. We took some risk, and we think it's going to pay off.

So we talk about comeback in our launch of olanzapine, and this demonstrates that it's a comeback at scale, meaning that there's still a really high unmet need despite so many options of therapy. As I said, most patients are on oral, and staying on an oral medication in this disease area is really, really difficult. When they break that pattern, obviously adherence breaks, relapse happens, there's more lost function, it escalates the isolation. It's this whole circle over and over and over again. So for appropriate patients, we know that an LAI can support adherence and deliver ultimately fewer relapses. It helps them stabilize and deliver their own comeback. So even better, as I said, we have two molecules. So we really take our leadership very, very seriously in this space because we have this optionality.

So now when we go to talk to physicians and they tell us this, we don't need to tell them that, they love UZEDY for patients that are on oral risperidone or oral paliperidone. They think this is a perfect fit. Now we can add to that WELTRUZA will be the perfect fit for someone that's on oral olanzapine. Together, we tackle most of the market, so it's a very broad range of patients that now would benefit from either of these two compounds. So our secret sauce, what does that look like in this particular area? Well, we know this patient journey well. That slide that I All the squiggles, my gosh, we live and breathe this.

Because it's very, very complicated depending upon where you live in the U.S., and even where you live in a city like New York, you could get treated in very, very different points of care depending upon your insurance or where you just absolutely happen to live. We have best-in-class patient services, and you might say, "Well, what are those?" So these are the things that help once the patient gets a prescription, get the prescription, and stay on the prescription. There's many, many things that intervene in that process because you can appreciate that if you have this disease, you've got a lot of other things at play. So helping, getting support to help manage that is really, really meaningful. We have established relationships in CNS, and so now we'll add another product to those already stellar relationships.

This really invokes kind of our right to have really candid conversations about education and about adoption and about LAI utilization much, much earlier. So I always tell the team, I'm particularly proud of this because they demonstrate that they get great products, they have a deep know-how, and they're incredibly passionate people. This recipe has really served us well in this space with UZEDY, and will do so with WELTRUZA. Let's take a look at our next launch opportunity. Ecopipam is really a very special product, and I'm delighted that we have it in our bag. It's not just another launch. We were, again, very purposeful about this because it's a strategic opportunity to add to what we already know in the movement disorder space with AUSTEDO. We also really know, especially from AUSTEDO, how to help an underserved market and underserved patients.

The patient population is about 100,000 children, many diagnosed, which is a really, really good thing, but still a very high unmet need. Tics show up between eight and 12, right when kids are going to school and kind of getting into the rhythm of their social relationships and establishing themselves. This also happens to be when kind of their functional and social challenges kind of collide, and the challenge is at its greatest. When we talk to children and their families, the kids describe themselves as, "I just want to be a kid. I just want to get through my day and have fun." Families are saying, "Gosh, we need effective care," and that's not necessarily available. Let's take a look at the journey very briefly from the vantage point of an eight-year-old boy.

We chose a boy because boys are more likely to have tics. It shows up much earlier in their life. They can see them, families can observe these when they're one, two years old, but diagnosis takes a long time, and they don't necessarily recognize that it's a tic or Tourette's. Some of the things that inhibit diagnosis is that they have to have persistent tics for at least a year. Then there's delays having access to specialists, getting referrals from their primary care or pediatrician. It takes a very, very long time. Then once they're diagnosed, the treatment options are not great. Most physicians say that they start with alpha-2. It's off-label, but they do that because there's very limited side effects. It might not be as efficacious as they need, but they don't want to harm the child for obvious reasons.

If that doesn't work, and with the family's blessing, they then often go to antipsychotics. Definitely more effective, but massively more side effects. You can appreciate, as many of you are parents, that that would be a really, really hard trade-off to make. Ecopipam, if approved, has this optionality now for a product that is approved for Tourette's, and it balances this efficacy and tolerability scale, and really provides a much, much needed option. I have the opportunity today to have you not just hear what I think about ecopipam and how great it is, but we have a special guest that's joining us, and it's Dr. Don Gilbert, and I'll give you a little bit of his background. He's a pediatric neurologist who specializes in movement disorders, and he's professor at University of Cincinnati in the Department of Pediatrics Children's Hospital Medical Center.

He was our lead investigator for ecopipam and has authored many, many articles and publications on Tourette's, and he is the resident expert. Welcome, Don. Thank you so much for being here. I love this because I think this will give you guys texture, and I'll ask a lot of questions that I think might be on your mind just so that you can have an appreciable interest in the disease. Maybe, and I hope this doesn't put you on the spot, but we've gotten to know each other a little bit, and one of the things I said is, "How did you ever learn of ecopipam?" Don told me this story that made me laugh and also just tells you how serendipitous sometimes occasions can be. Do you mind sharing that with the group?

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Sure. I am on the spot, right? Because there is this bright light on me and I am on this stage in front of people I do not know.

Chris Fox
EVP, Teva Pharmaceutical Industries

It is among friends. It is fine.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Just maybe to back up one

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

little bit, to give some context. I finished my training in 1998, and in medical school and in residency, people would say to me, "Why do you want to go into child neurology? You cannot do anything for those patients." And I would say, "Well, somebody has to do it, and it is very interesting." And I believed I was starting my career at a time where big things would happen during my career. I have a clinic in Cincinnati Children's that is a movement disorder clinic, so we see dystonia, tremor, ataxia, chorea, myoclonus, a lot of things that interfere with voluntary movement. But the most common thing that we see is kids with Tourette syndrome. I am seeing kids with Tourette syndrome, and I am participating as a site investigator early in my career in a few trials, but nothing really is happening that is that exciting.

And then I get this phone call out of the blue on one of my research days, so I am not in clinic, and my admin, it is early in the morning, my admin says, "There is this guy on the phone that wants to talk to you about a possible new treatment for Tourette syndrome." This is 2009, and that guy was Dr. Rick Chipkin, and I had actually remembered his name from publications in mouse research from the 90s about the dopamine D1 receptor.

And I had always wondered since medical school, if the brain is full of dopamine and it is full of dopamine receptors, why do all the drugs target the same receptor, which is the D2 receptor, and nothing targets D1, especially when D1 is really important for movement? Anyway, this guy is on the phone. He says, "I have a medicine that is a D1 blocker.

Do you think that would be good for tics?" And I said, "Where have you been all my life?" And he said, "Well, are you free this afternoon?" I said, "Yes." And he said, "I am going to fly out there right now." So he flew out to Cincinnati with a pharmacologist. They had these binders. We met at the bar at the CVG airport, spent several hours talking, and I was learning about ecopipam. In the end, I promised that I would try to get a trial going, and so we started the first trial in 2010 in adults that had Tourette syndrome. So that is kind of how I first got involved with this medicine.

Chris Fox
EVP, Teva Pharmaceutical Industries

Awesome. Yeah. I love that story, not just because it has binders and a bar, but just generally, like, how serendipitous that someone would directly just call you. Obviously, he knew who you were, so that makes sense, but-

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

We stayed sober.

Chris Fox
EVP, Teva Pharmaceutical Industries

Well, that's good because he made a really good decision. Maybe we could start a little bit with diagnosis and some of the treatments available, because I think that will set the stage for some of the other things that we'll talk about.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Sure. Any parents here? Yeah. Parents watch their kids all the time, and so they'll see their kids typically sometime in early elementary school or before the age of 10 start having tics. This may run in the family, because it commonly does, but they're watching their child and they're thinking about, "Is this interfering with my child's quality of life?" At some point, they become concerned that it is, and so then they bring them into our clinic where we see hundreds of kids per year with this symptom. Essentially, we know when they come in that this is commonly co-occurring with some other problems. We try to comprehensively assess them, and for each thing, decide, is this interfering with this child's quality of life enough to intervene or not? The formal diagnosis isn't really the issue.

Tourette syndrome has formal criteria, just like schizophrenia and lots of other things. But the main thing really is, what's the symptom that's interfering with the child's life, and is it interfering enough for an intervention? Sometimes at the first visit, sometimes later, we make a decision with the family to intervene, and the intervention is based on practice guidelines, although there's a lot of variability in the way that doctors practice around the world. We follow the practice guideline, which is to discuss medications and a therapy called CBIT, and just decide with the family what's the best fit for treating them.

Chris Fox
EVP, Teva Pharmaceutical Industries

Can you talk a little bit about some of the treatment options?

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Sure. CBIT is a therapy. It is kind of like therapy for OCD. The medications, neurologists are used to not having good treatments, so we are resourceful. Everything that we have really been doing for years is stealing drugs from other indications. Basically everything that we used for Tourette's until the last 10 years was off-label, and it was designed for something else. We start out with medicines that are antihypertensives. If that does not work, we know that there is a class of medicines that is FDA approved, but we do not want to use them, which is the antipsychotics. Almost always in our practice, we try at least one other medication, either an anticonvulsant, which was not designed for tics, or a muscle relaxant, which was not designed for tics.

If none of those is successful, then we move on to the medications that we know have the highest chance of working, which is antipsychotics. But the families often do not want that, even if we reach that point. We also have to worry about adverse events in that pediatric population sometimes being worse than what we are treating.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah, that is a great point. You and I have talked about some of your patients that you have followed for years and their experiences. I think it would be really interesting for the crowd to maybe get a glimpse of that, if you would not mind sharing a couple examples.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Sure. The cool thing about going to a city and staying there, if you have got a condition that runs in families, is that I am just getting my phone out here because I have some cases. Is that you often get. Actually now I am seeing kids with Tourette syndrome whose parents I took care of. But we have this thing called Epic, and we have this thing in Epic called MyChart, and MyChart gives families access to us all the time, which has its good side and its bad side. But I thought it would be helpful for people to get a real impression of what it is like from the parents, so I am just going to briefly read to you from two MyChart messages that I got from kids that I see. Here is the first one, MyChart message to Dr. Gilbert.

We wanted to give you an update on Cameron and get your guidance. Since school and football started, we've noticed an increase in Cameron's tics. We discussed this with Cameron, and he's finding the motor tics painful, mostly the back bending and the nose tics. He's been experiencing several nosebleeds per day due to his snorting tic. It's very difficult to get the nosebleeds to stop. We would be available to meet with you in person, virtually, or to try any medication recommended that you have. This is one of my patients already. He's already prescribed a D2 receptor antagonist that's FDA indicated. He already failed tic therapy and two other medications before that. So what do I have to offer?

The second patient, "We've increased the new medicine to one and a half pills twice daily for four weeks now and really aren't noticing any difference in Joey's tics. We feel like we need to do something. He's really sensitive about being overweight, so we don't want to try that medicine that you mentioned in clinic that causes weight gain. Are there any other options?" He had already failed tic therapy, and this was his second medication that we tried. So we're at the point where we would typically try an antipsychotic or a D2 block for him for his symptoms, but they don't want to because they're worried about the most common side effect that we see in kids, which is unhealthy weight gain with that class of medicines.

I can offer him, again, another medicine that's been stolen or borrowed from some other indication, but I don't have anything that's specifically developed that targets one of the main pathways in Tourette syndrome, which I think ecopipam would as a D1 blocker.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah, that's amazing. You said something that I want to ask you just a double-click question on, and that's the nosebleeds from tics in your nose or in your back. I don't think most people think of it that way. I think they think of a verbal, all the things that get publicized about Tourette's is very specific. Can you say more about the other types of tics that people are dealing with?

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

So, it varies a lot. People have their own, what I call their repertoire or their group of tics that they do, and in childhood, those often change. In the adults that we see, they may have a set number of tics that they keep for decades, but kids' tics are always changing. Most tics start out with something that you would do ordinarily, like we all blink, we all roll our eyes. Sometimes that gets misinterpreted. We all sniff, we all clear our throat. Kids that have a ticky brain turn those things into tics, so most tics early on are regular behaviors or movements that we all do, or sounds that then are released many times through the day unnecessarily, either involuntarily, automatically, or after an urge to do it.

If they persist into their teenage years, especially if they have OCD, which a lot of them do, then they often have some of those more complex tics that you might see on TikTok or YouTube or something like that. But like many things, it is the most extreme version that you see in the media.

Chris Fox
EVP, Teva Pharmaceutical Industries

Absolutely.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Yeah.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah. Well, I just imagine some of these, like putting myself in the patient's shoes, they could be painful. I mean, it is not just that it is annoying and obtrusive.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Well, so you are taking a standardized test in high school.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

You have got to be quiet for an hour, and you have got vocal tics.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

What do you do? You think about not bothering the other kids with your vocal tics, taking up some of your brain power that you could be using on that test, and then maybe you do it anyway and the class is mad at you.

Chris Fox
EVP, Teva Pharmaceutical Industries

Mm. Yeah, for sure. That is a great example. Maybe tell us a little bit about your experience with ecopipam and some of the patients that you have treated. What have you seen? What have been their experiences? What is a good patient for ecopipam?

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Yeah. Doctors are funny scientists because scientists just want the truth, and that is what we want too, but we also want something that works.

I have been an investigator in all four of the studies for ecopipam and Tourette syndrome, and then those studies all had open-label extensions. Sometimes the patients then would continue seeing us regularly for a year or two years afterwards, and it is a lot of work for them. A nice thing that happens for us is that we really develop strong relationships with the patients, and I can watch them sometimes for a number of years. I would say the kid that has been in the study the longest was in the phase II study, the parallel design study where it beat placebo. He then rolled into open label, and when the open label was over, his parents were very upset because they did not want to stop it, because this had really helped him a lot. We went through the paperwork.

We actually put him on risperidone for a few months because paperwork takes a long time. It is a lot of work. He gained unwanted weight, but once we got the paperwork done, we rolled him back on ecopipam. The weight came off. He is now in high school. He did the compassionate use, and then he rolled into the phase III open label. He has probably been on it for over four years now, and he has done great. He is socially accepted by his peers. He does sports. His grades are good, and his tics are in such good control. If this were on the market, I would take him off it now to see how he is doing, but they do not want to take the risk in the middle of high school of coming off something that seems to be working that well.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah. That is compelling, for sure. Why would he want to stop? I know we are kind of up on time, but I want to invite you, if there is something I should have asked you that I did not, what have I missed that you would want us to know?

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

Well, I mean, I would say in neurology, we do not say diagnose and adios nearly as much as we used to. That is because really a lot of science that started out in the lab has been translated by industry into things that really make a difference for our patients, and the families really want this. They do a lot of work to be in a clinical trial. They have to get EKGs and blood tests and do lots of extra visits. Everything that each of us or our family members takes happens, as you know, because people volunteered to be in these studies. I have a huge debt of gratitude for the families that have been involved in the study, but I am also really grateful that people are working to get new treatments to my patients. Thank you for your interest in this.

Chris Fox
EVP, Teva Pharmaceutical Industries

Well, that's amazing. Any advice that you have for our commercial team? I know they're not here. This is an audience of investors, but I think that this is important, one, to demonstrate to you that we're always learning, but obviously you're the expert. So what should we be thinking about when we approach this market and physicians that are treating Tourette's or don't know that this is going to exist? What should we impart on them?

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

I think it's really key to emphasize that this is different. This is not a me-too medication. It's not a repackaging or reformulation of something else. It's really its own first-in-class medication. And the doctors that I've talked to that love their jobs, like me, are following the literature and they're following the studies.

Chris Fox
EVP, Teva Pharmaceutical Industries

For sure.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

They want this. I think I would probably, if I was going to emphasize one thing, I would emphasize that it's first in class, and it's hard to beat placebo in a lot of clinical trials.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yes. Yeah.

Don Gilbert
Pediatric Neurologist, University of Cincinnati College of Medicine

It beat placebo. It is a first-in-class medication, and I think there will be a lot of enthusiasm about this from people like me that love our job and want to help our patients.

Chris Fox
EVP, Teva Pharmaceutical Industries

That is awesome. Yeah. I think that that is going to be a big part of our intent, is education and getting the word out there. We look forward to you helping us spread the word. Thank you so much for your time and really, really appreciate it. Thanks. Thank you so much. That was awesome. I hope you guys got a little bit of flavor. We get to do that all the time, and I thought it would be interesting for you to get a little behind the scenes. I am going to close on ecopipam, on kind of where we are going to focus, and building on kind of my last question, because it is purposeful. Obviously, we do lots of research, but you can see that this patient journey is real. There is no really great option.

Either it does not work, or it comes with side effects and trade-offs that is pretty untolerable and has consequences. We are going to gladly take this product, ecopipam, into our armamentarium of all of the things that we expect to do and build on our movement disorder experience from AUSTEDO. We know that there is something special about children and their families, and that is going to force us to think about this differently, but we will do that certainly very respectfully.

I think the other big thing is that you heard this trade-offs that families have to continue to make. We have to be really clear on this education bit. The very left hand of the slide of what are the trade-offs and what is the benefit and the safety, knowing that this works. One of the things I heard Dr. Gilbert say is, we also need kind of urgency, right?

To make the burden real. These kids are really dealing with this, and even adults and young adults. It is incredible how complicated it makes their life. Energizing, I meant to ask him this and I neglected to, is, we have talked a lot to physicians in market research, and because they are children, they also wanted to have a wait-and-see approach. That is not in the best interest of the patient. As a team, commercially, we are going to try to really create some surround sound on, "Hey, let us drive this clinical conversation because it should happen now." Our hope is that this better option really transforms Tourette's care with an opportunity that is going to be very, very meaningful. Now I want to switch to dexmedetomidine, and this is a potential at-home treatment for acute agitation.

Another really strategic acquisition that I think plays to our strengths in understanding the schizophrenia foundation and parlaying that experience in a new way. As I said, for acute agitation, but specifically in schizophrenia and bipolar I and bipolar II, there are approximately 7 million patients in this space, and about 25%-40% of them experience agitation. Not just randomly or on a reoccurring basis. On average, it is about four times a month, so about 48 times a year. That is significant. This could be the first potential, first FDA-approved at-home treatment with great potential to address this, to really be where they need the treatment. A strategic fit because of our know-how in schizophrenia, really understanding this market, leveraging our existing infrastructure that we already have, and the prescriber overlap.

Our intent is to build on those relationships and launch this product in extraordinary fashion, and building value incrementally in a space that we already know. We are really, really excited about this, and we will keep you updated as we learn more and take this through. Next on DARI. David, you did an excellent job of kind of teeing this up, and I will just hit some of the couple of highlights that I think are really relevant for the commercial vantage point of this handoff that happens. 27 million asthmatic patients, really significant patient population, and importantly, about 3 million of those are children and adolescents. About 13 million are treated, which you kind of say to yourself, "Okay, that is pretty good," given the case, it is about half.

11 million of those are only on the SABA part that David talked about, and so that is the short-acting part, the beta agonist part, that is typically used by most physicians for an acute exacerbation. They are having an attack and they take that short-acting beta agonist. There is this need for ICS, the other component that addresses the underlying disease and really the inflammation, so the inhaled corticosteroid. What is good about this is the guidelines already support this, so it is not like we have to go convince experts that this should be the case. This is already widely known. But compliance is very, very hard, because in most cases, the optionality is that they can take two inhalers to get this combo effect. What is great about our solution for this and our DARI is that it is incredibly easy.

The first thing is that for pediatrics, really, really important. We will be the first with a pediatric indication, and then a major advancement in the device. The device is obviously a big part of any patient experience, but especially you can appreciate for a pediatric patient. It is the open, inhale, and close. Super easy, almost so you do not need to think about it, especially if you are having an attack or you are taking it as you should on a routine basis to address that inflammation. No priming, no shaking, no spacer. It is a real hassle, and then you have to carry this thing around. There is a huge cleaning process. It sounds ridiculous, but all of these things kind of add up to products that do not really get used. Pending regulatory approval, we are really excited to add this to our respiratory experience.

We have a lot of know-how and foundation in this space as a corporation. I kind of want to level back up and zoom out, and we saw the products of this entire portfolio over the course of time. What I would say is that we are really anticipating all of these handoffs and how this is going to happen. I would say as a commercial leader and an enterprise leader, I think what also makes me really excited is it is not just a one-hit wonder. We are not looking at one asset and betting the farm on that, and I have been in a lot of companies that that has been the case. It is the next big thing, and everybody rallies around that.

That can serve its purpose, but what I like about this is the de-risk nature of our portfolio and how that makes the likelihood of it ending up in our bags much, much higher. The certainty that it is going to get in patients' hands is what I take away from the presentations this morning, that we are going to have these products and be able to intervene and bring them to patients. When we translate that of how do we take all that science and build a value proposition for patients, but also for our company, this is where it really comes together. This is our aspiration, and I think we are still sorting out all of the final numbers and what the opportunity looks like, but we know emphatically that it is over $10 billion.

When you think about that in the context of where our companies come from, it is not just meaningful for patients, it is also meaningful for where we are headed and the kind of company that we are building. Richard pressure tests us all the time on, "Why do we have so much confidence in commercial? Why does it feel that way?" He showed you some of this, but I think where I would like to start in saying that I have a lot of confidence in my team, and I think that they are really extraordinary at what they do. A lot of the proof points are in these last couple of years, a lot of the things that we have done. I will just name a couple.

There are so many that I could pick, but AUSTEDO hitting $2.5 billion a year earlier than we anticipated, and really fueled from consistent growth, seven quarters, quarter-over-quarter, double-digit TRx growth. That is extraordinary in any product, especially one that is nine years old. I mean, it is incredible. AJOVY, our number one global injectable CGRP. This is important because it is our first real global asset since COPAXONE, and revenue fueling growth at 61%. It is incredible.

UZEDY, nine quarters of fastest-growing LAI, and probably more importantly, launching into a very crowded market, but relatively small, and we have doubled the size of that market, which in my career, I do not remember too many times that you can launch a new product and make such a massive difference because the product was differentiated in such a meaningful way that it made our jobs easier to have that value prop be really, really clear. A couple other things I will just share. Since 2022, our innovative revenue went from about $1.3 billion to predicted $3.8 billion-$3.9 billion this year. And probably more importantly to my team, and this is what we live and breathe, is that we have gone from about serving 4 million patients in this space to over 10.

That is an awesome calling card to say that we can really make a difference with the right approach. That is kind of what we have done, but I think it is also important the how. I was not being cheeky when I mentioned secret sauce at the beginning, because I really, really believe that this is a part of why we are successful. I will start with the right-hand side and work my way back. In totality, these are five capabilities. Likely every company that you cover has these to some degree, and they are kind of standard fare for But how we do them is really, really different, and I will talk about that here in a second. I think the other big difference is that these do not work independently. They do not sit in silos next door to each other delivering their work.

It is very synergistic, and our commercial team works really hand in glove, not only with R&D and BD, but amongst ourselves. The first thing I will mention is the advanced analytics, and this has been something that since I have gotten here, I think we have had exponential growth and productivity in.

We now are really accustomed to using machine learning and AI for solving really practical day-to-day problems, like doing a chatbot for reps so that they know where everything is really easily, but then also solving really complicated things like who is going to be the next UZEDY prescriber that has never written an LAI? How do we suss that out, and how do we figure out how to expand the market even more? These are things that we use every day. We use it every single quarter in market access, which is becoming a growing strength of ours.

For those of you that I have had a chance to sit down with in smaller group meetings, you know that I always say that we are solving for as broad of access as we can possibly have for as many patients as we can have. We also need to make sure that we preserve the value of the innovation. Companies tend to do either one really well, they give access to everyone, and then it creates a seismic problem for making that product sustainable, or they come in at too high of a price or discount too much, and thus do not get much uptake. Getting this part right and using analytics is a really important part of our business value proposition. Our marketing team, I mean, absolutely unbelievable.

They are excellent at launch excellence, the market research that they do to understand the patient journey, and all of the things that I have talked about around the outskirts of launching WELTRUZA, really, really great at growing and building markets. Patient services, this is a new one for Teva. Some bigger companies do this really, really well, and they spend exponentially what we spend. These are services that allow the patient to get support, so when they get that script and have difficulty figuring out their insurance or cannot even get it filled, what do they do? How do they do that? It works in the confines of whatever their current situation is. Then also to help them stay on the medicine, and as they have questions or need other support, that we are there with them every step of the way.

You can appreciate when I showed you the schizophrenia patient that for someone like that is incredibly important. I saved it last, but it is probably the most important part is the customer-facing team. All of that stuff really matters, and it produces better outcomes, but only if the tip of the spear are people that have great relationships, are trusted advisors for their doctors and office staff, and this is something that we have done and continue to do exceptionally well. I said it earlier, and I say it to my team all the time, it is extraordinary because it is great products, a really deep know-how, and passionate people. I continue to be really, really confident in their ability. It is a powerful thing when you all are aligned and working for the same shared goal, and you know exactly your role.

You have clarity of purpose because you are understanding how you are going to individually contribute to the overall success. Lastly, I would say one of their gifts is that they are incredibly accountable, not just to their patients and their customers, but also to each other, to our company, and ultimately to you guys. Thank you so much, and now it is my pleasure to introduce our CFO and my friend, Eli Kalif.

Eli Kalif
CFO, Teva Pharmaceutical Industries

Good. Thank you, Chris. Welcome, everyone. I appreciate your interest in Teva, and it is a pleasure to see you all today, and thanks for those who are joining us online. Last year at our Capital Markets Day, I told you that we are transitioning into a biopharma company. Today, I am proud to tell you that Teva is a different company and has become a biopharma company, and we are going to discuss it today. What makes us distinct from others across the industry is our agility and ability to act with speed. For me, the CFO, I am constantly looking to allocate resources and prioritize capital deployment and to enable high-velocity environment.

Today, I will share with you not only the exceptional performance that we were able to achieve as we transition into becoming a biopharma company, but also to show you how we will keep allocating capital in order to grow our innovative business and to create shareholder value. I will walk you through 2030 outlook. This outlook by itself have a great optionality to create a significant uplift to our shareholder value creation. Managing a massive wallet with over a $10 billion of annual spend during a corporate turnaround, that can get messy. Our approach enable us to achieve shareholder value. Today, I will show you how we are going to continue to create shareholder value as we are entering into high-velocity biopharma. What you see in these slides is the three ways that enable that.

To understand better the wallet, let me just remind you that last year at our Capital Markets Day, as part of our transformation, I mentioned that we have three main pillars. First, we are modernizing the organization. Second, we are actually able to resource allocation and at the end, optimizing our spend. Resource allocation doesn't stop at the P&L level. Not at all. We actually continue to transform our balance sheet to a much stronger version. We leverage our generics powerhouse to fund our growth engine. We generate significant savings in cash at the P&L, and you know what? We didn't actually put them in our pocket. We reallocated them, we reinvest them, because we need that cash and that savings in order to fuel our growth engine and clinical pipeline.

We started that shift less than four years ago when we established in 2023 our Pivot to Growth strategy. Now, I want to show you how far we have come. This is the pure reflection on how Teva emerged to become a biopharma company. As a wise CFO knows, you know, narrative doesn't matter without the receipts. From my perspective, what you see here is nothing short of dramatic. We are able to fund the revenue growth. We are able to change totally the margin profile. We reduced our debt. We cleaned the runway through 2030 with lower maturities. We are able to cut our financial expenses with approximately savings of $1 billion for the next four years. We dramatically and significantly improve our working capital. Lately, we are recognized by all three rating agency and become fully investment grade.

On that point, let me just tell you that Teva is the first ever company that become investment grade with all three rating agencies in less than four months in the same calendar year, skipping outlooks, and we did it one year earlier than the expectation. You know what, looking on this one, on this performance, saying again, high velocity, it is like rebuilding at a foundation of a skyscraper while the tenants are still working inside. It is about demonstrating the discipline, agility, speed. This is thanks for our team and to the remarkable culture that we have been building in less than four years. Now, let me show you how we are freeing our capital and investing as a high-velocity biopharma. Again, our ability to allocate capital with agility, it is critical. It is about the discipline to take out those freed-up capital and reallocate it with speed.

For examples, let us say we are cutting investment with lower margin profile. Then we are doing it, let us say, on Friday, and the following Monday, we are able to get those funds ready to go and do two things: fuel our growth engines and keep financing our BD and R&D. Basically, what you can see from this chart, we took third of our gross profit margin and reinvest it back in the business. Overall, in the last four years, we put to work around $1.7 billion coming from working capital enhancement and financial partnership. What we did with that, we actually went back and invest in R&D and have the ability to invest in business development. At our Capital Markets Day, I also mentioned that we are moving from 40% mix of innovative R&D investment into the level of 75% in 2027.

From what you can see from this chart, we are right on track. But what you cannot see in this chart is the fact that our innovative R&D spend is more than 20% from our innovative revenue. Now, going further, let us see how we are thinking about continue to prioritize our capital. Now that we can say that we are high-velocity biopharma company, we continue to strategically allocate our capital. What it is doing, it is drive return, sustain our growth, and creating shareholder value. But now, with a stronger balance sheet, better liquidity, linear working capital, and higher cash conversion. But what this one is doing, it is creating a lower cost of capital. For me, as a CFO, I need to make sure that we have the ability to prove that all those strategic moves that we are doing have a solid return.

This is exactly what I mentioned while saying managing a massive wallet. On this slide, you can see how you focus in those three areas will enable us to demonstrate so far nice returns. First, look on our growing our core engines. We just mentioned last week in our earnings that we are yielding to almost $4 billion with our three products, AUSTEDO, AJOVY, and UZEDY. This is amazing, and we are going to see it as it is moving forward. Our pipeline accelerate approach using partnership, the speed of WELTRUZA development and approval will help us to enable and address massive unmet medical needs in the market. Last things, this is about BD. You saw us doing few deals this year, targeted de-risk transaction with a strategic fit. You heard Richard, Eric, and Chris mentioning today about launching five products in five years.

Getting to that level of scale is totally different, but we have now better liquidity, better flexibility, and totally different balance sheet in order to create that value from those late-stage pipeline. Now, to really understand our transformation, I want to show you how we benchmark our performance versus the industry. You heard Richard. We are strategically performing as a biotech mindset while operating as a biopharma company at scale. Looking at this chart really make me so excited to have delivered such great KPIs. This is a clear reflection on the significant improvements that we were able to make inside our business, recognized by our investors, and really resulting with a significant improvement on our valuation. This is creating shareholder return. That performance put us ahead of 19 of 20 large biopharma companies.

We will continue to use finance to drive shareholder value creation, and what I want to show you now, how we are going to do it while looking on our future innovation growth. I really like this slide. Let me tell you why. Because that provide a clear evidence on how we are operating as a biopharma company at scale. As you can see from the chart, looking on the revenue mix shift, in 2022, we had only 10% innovative revenue, with the vast majority of the business tied to a lower margin generics profile. Now, look on 2026, just four years later, we are now with 20% on innovative revenue. We did it because we were able to deploy capital into our innovative business, again, to drive returns, to accelerate growth, and to create shareholder value.

The growth from 2026 with almost $4 billion on innovative revenue heading to $6 billion-$7 billion in 2030, that is going to set totally different agenda for me as a CFO. We will need to keep growing our core engines, and second, we need to invest in those product launches. Therefore, gross margin will grow now, year-over-year, reflecting that revenue shift. That margin expansion, this is the financial reward of the pivot right there, and we will continue to expect for that growth. When you look on 2030, with more than 25% of innovative revenue, gross margin more than 60%, free cash flow will expand, working capital going to be negative. This will allow us for better option to invest and to create shareholder return. We will going to accumulate more than $11 billion in free cash flow in the next four years.

Now, of course, if operating margin is increasing, EBITDA will expand. If EBITDA expanding and we are reducing finance expenses, we understand that we are going to grow EPS even faster. I spoke about how we are prioritizing capital, and I want to address also how we are going to keep being disciplined to our capital allocation methodology. Again, in May 2025, I mentioned that we are going to keep the leverage to the level of net debt to EBITDA to two times by end of 2027. I also mentioned that we are going to keep that ratio and to position ourself to sustain our growth. I am here to tell you today that we are not changing it.

But now, what changed that we have enough headroom on our balance sheet with a lower cost of capital to do three main things: keep acting on sensible business development, support our R&D, and keep fueling our growth engine. And of course, keep the optionality to return to our shareholder through buybacks if it is appropriate. Now, ending to my last slide before turning back to Richard. Some investors may say they have missed the bus with Teva. I am not going to comment on that one, but I do want you to look on this slide. Building on the last four years of execution and looking on the next five years, where we are going to continue to see our innovative revenue growing along with the innovative pipeline, we are uniquely positioned to keep deliver accretive shareholder value.

And even though that we have been a top performer in the market, we believe that our shareholders will be rewarded as we continue to be successful on our execution with our Pivot to Growth strategy. And I want to end up with what one of our bigger investors told me when we got the investment grade upgrade. He told me, "The balance sheet is in a great place now, and I know that there is more incremental work to do, but Teva is in its next phase. The pipeline, the cash flow, and the business development opportunities will all yield to a benefit to Teva, to the patient it serves, and to the shareholders." And with that, I want to hand it back to Richard.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Thank you, Eli. The good news is I just have one slide, and then we are going to go to a Q&A. But I stand here exceptionally proud, actually, of the team. Not just the quality of the presentations, but it is all about substance. And the substance that I think is being presented here today should really create a lot of good conversations, a lot of good conversations about where Teva is going. I am going to summarize on this slide. It is an extraordinary slide.

I have been in the industry 35 years, and I have worked for some amazing companies, but I have rarely been in a position where we can launch innovative products, not just every year for the next five years, but have a line of sight to the next wave of innovative products. And by the way, I hope you see the quality of the R&D strategy.

It is very pragmatic, but it can deliver exceptional returns for the patients and for the company and for the shareholders. Because of that pragmatism, we are designing things with the patient in mind all the time, even though we are touching upon some quite extraordinary science. And when you look at that, what that can do for us financially, once again, is also very extraordinary. To be at $6 billion-$7 billion in 2030, and then the double-digit growth trajectory we have after that, allows us to keep reinvesting in our pipeline, allows us to keep reinvesting in driving growth, whether that is through business development. And by the way, the way we look after capital at Teva maybe comes from the years when that was pretty scarce. So we really think hard about the return on it.

We really think hard about how we apply capital internally, where we place it, which is why our agility about moving it is there and will always be there. When you think about this from To take Eli's question, when people said, "Have you missed the boat?" he said he wouldn't comment on that. I will comment on that. What I would say is, while the last 3 1/2, nearly four years has been exceptional for what the team has done, I would say that based on what you've seen today, based on the products we've launched already, which are either AJOVY, AUSTEDO, UZEDY, WELTRUZA, we have $5.5 billion of peak sales there. We are about to launch ecopipam, dexmedetomidine, then we have duvakitug coming. Our line of sight to the $6 billion and $7 billion is very clear.

What I'm already focused on, what the team are focused on, is how do we maximize those assets we have and continue maximizing that. As I said right at the start, an innovative product in the hands of Teva will be optimized, I believe, like no other company. When you look beyond 2025, sorry, 2035, we have more and more assets coming down. I go back to those four products which are pipelines in a product, as well as a very selective and thoughtful approach that we have to BD. We have a great organic pipeline, but we want to keep expanding that, we'll critique that constantly about what is to come and what is external. With that, we have opportunity to keep driving the margin, which I'd ask you to look at.

I know it's unusual to look at gross margin for a biopharma company, but please look at ours. While the number's 55%, you better look at it quickly because it will keep going up. That's really unusual in a biopharma company, because normally what you're trying to do is stop it coming down. Look at that, then look at how we invest that money, how we manage our OpEx, how we grow our EBITDA, and how we grow our EPS. With that, I really want to say thank you for your time and attention. Now we're going to go to a Q&A where you can maybe critique some of the information you've heard today, challenge some of it, question it, or maybe expand on the tidbits we've given you today and go a bit deeper.

With that, I'll ask my team to come up onto the stage, we'll hand the mics out, and we'll take some Q&A. Wow, that's a quick one. Do we get a mic down here?

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Hold on. Give us two minutes, and we are going to put chairs up there.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Well, we can take that. We can do it standing, hey? Because I think we have gone on a bit longer, so let us just do it standing, yeah? Is that okay?

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah, of course.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Do we have a mic?

Speaker 7

[Presentation]

[Presentation]

Chris Fox
EVP, Teva Pharmaceutical Industries

Just repeat the questions so everyone can hear.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Okay, yeah. I think first quick question here, yeah.

Jason Gerberry
Analyst, Bank of America

Hi, Jason Gerberry from Bank of America. Thanks so much for doing the presentation. Just two questions, one for Chris, one for Eli. So maybe for Chris, now that you guys have had a chance to crystallize a little bit more your views on ecopipam, just curious how you think about the importance of safety and safety labeling and avoiding sort of D2 class safety effects in terms of driving sort of that commercial outlook. Then for Eli, in terms of thinking about where you are from an R&D spend perspective, appreciate the added granularity. It looks like you are spending close to 20% of innovative R&D as a percent of innovative sales. So just curious, is that the right way to think about the trajectory as the brand business grows and how you fund all of the programs that you have outlined today?

On the other side of it implies only maybe $300 million of R&D for generics. That is about half of, I think, what generic companies, big generic companies like yourself have spent in the past. Is that sustainable?

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Let us start with Chris on the first one.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yep. I am going to ask Eric to comment on the label part first, then I will tell you the commercial viewpoint of it, just because I think it is important.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

Yeah, I think you touched on the most important thing. Ecopipam is a D1 antagonist, not a D2. It's fundamentally different from everything else that's been tried in Tourette's. Two other comments I'll make is, we have two well-controlled, placebo-controlled studies that show an advance. Dr. Gilbert mentioned that that's hard to do. I think the AE profile is exactly what this market needs. I think that's what keeps people from getting effective treatment and staying on it. Remember, only about 25% approximately of people who get on a D2 antagonist stay on it. We had 66% of the people finish out a year after the study. That's one of the things. We don't have the metabolic problems, we don't have the weight gain problems. We didn't see any movement disorders.

Those are all things that I think Dr. Gilbert thinks about, but I would think about as a parent whenever I was starting someone on. I think the differentiation is there. The last thing I'd say is, a dedicated launch in Tourette's has never been seen before. I think the disease awareness and how we can drive the market, Chris's shop, will really make a difference.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah. I think, I mean, the net-net, based on what Eric said, is we expect a clean label. We'll have to manage that as those cards turn over. I do think a lot of this is going to be education, proper diagnosis. I mean, one of the things Dr. Gilbert didn't get into is there are a lot of different types of tics. What we don't have clarity on is how big is this market? It could be much bigger than just Tourette's. We also don't really have line of sight to like, how the practice volume, like how practices handle this based on what's available, because it kind of masks our ability to understand how many people have Tourette's versus other tics.

One of the other things some of the other investigators and Dr. Gilbert have said is, this might also be very effective in other tics because it's likely going to work. Once we get the label, we'll be able to tell you exactly what the situation is and what that looks like. But I think this is going to be really building a market that's been very underserved, and people are unfortunately, doctors are no different, are very habitual, and so we're going to have to undo some of that stuff and offer this better alternative.

Eli Kalif
CFO, Teva Pharmaceutical Industries

[Joe]?

Chris Fox
EVP, Teva Pharmaceutical Industries

This is on.

Eli Kalif
CFO, Teva Pharmaceutical Industries

Yeah. So for your question, it is a good question. Look, first of all, we need to think going further. We are going to keep reallocate part of our gross profit margin increase with the same way that we did, meaning we are not going to bank them. We are actually going to redeploy them in the business. So that will go either to sales marketing, either to R&D as we keep growing. So the margin actually will not flow 100% from gross profit to the OP.

They will stop somewhere at the OpEx. So that is one element. The way to think about it, although the chart that you saw, we try to be very transparent. This is a gross R&D. It is not net from the funding. So basically, you should think about between 15%-20% over the revenue of the innovative revenue going forward. You asked something very interesting on generics.

Look, the beauty of the way that we are working and combining in between generics and innovative is the fact that there are so many synergies. As you know, part of the growth of the generics, it is coming also with the biosimilars, which we mentioned now, around 31, 32 assets. The majority of those one are coming with a partnership where we have kind of a share profit. So the burden on the R&D is not on us.

Also on generics, as you know, when we mentioned it is part of our strategy, we are capturing actually lower LOEs. It used to be more than 90%. Now we are at the level of 60%. If you think about regulatory and other elements that we have in the company, those synergies enable us to run a very, I would say, low run rate in terms of the generics over the revenue.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Maybe one just thing to add, to build on what Chris said on the ecopipam. If you think about it, to really simplify it, what we have to do is not too dissimilar from what we did as AUSTEDO. It was a market which was under-penetrated. There was a physician lack of awareness that was a treatment. Patients were lack of aware that there were treatments. I think Chris's team has done that on scale for many years. So that is a muscle we have got, and that can be applied to ecopipam and Tourette's. So I feel we are in a really good place for that because it is not something we are going to have to start from scratch at all.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Thank you, Jason. Joe, you're next, and then Doug in front, and then Chris Schott, Les.

Joe Thome
Analyst, TD Cowen

Thank you. Joe from TD Cowen. Thank you everyone for the presentation. Maybe one on the clinical side with the anti-IL-15. Obviously, how quickly you're moving on the vitiligo side. We've seen some datasets in celiac this year, and some companies are kind of going right into phase III. Maybe what do you want to learn in the phase II experience in celiac on the endpoint side of things or dosing before you go into a phase III program? Then maybe for the bispecific, trispecific pipeline that you outlined, how important is partnerships there, like you did with Sanofi with duvakitug?

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

Okay, yeah. I'll start with that.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

I think you better. Yeah.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

You said clinical, so I will jump in. So with the phase II study, we can build upon what we have shown in the proof-of-concept study. The data was very positive, as David had pointed out. Everything went in the right direction. We have a much greater sense of what we expect as our point estimates on a number of points. It is not commonly known, but we actually ran two celiac disease studies. We learned a lot from the POC, the first one. We applied that knowledge to the second one. I think that is probably why we had such a great execution on that study. So we are going to apply those learnings into the phase II. I think the most important things are, how do we expand upon the symptom improvement we saw? It was not statistically significant in that study, but it was a small study.

Now we know what moves. We know very clearly what we will expect on the biopsies. So those are the two main components, the symptoms and the biopsy results. Then it is in negotiation with the FDA and with our advisors about how we will interrogate it. Actually, I do not want to spill any beans here, but I think the team is coming at it in a very novel way in how we will look at the populations of preventative versus treatment of patients.

That is going to be key, because my aspiration for celiac disease is we treat everybody. There is no reason that we should only limit it to people who cannot respond to a gluten-free diet. People who can respond to gluten also want to eat normal food. So I get a little passionate about that. I apologize for that. But that is our aspiration in the program.

We will apply all the learnings we have learned from the two studies we have done already. Your other question about partnerships in our bispecifics, our trispecifics, our ADCs, all the fun stuff we have in the pipeline. Maybe I will start off by saying, I think by then, we will have a machine that we will develop those all ourselves. I think when we started the Pivot to Growth, we had an embarrassment of riches. We had to move quickly on everything all at once. I think by then, we will have a much more understandable, stable, and executable large inflammatory program at that point.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Yeah, maybe I would say that last point about partnerships. So, the principle we have here is if you find something that works, the one job we have is to get it to market as fast as possible in as many indications as possible. That is number one, and it is number two principle, and it is number three principle. Because it happens so rarely you find things that work, and if they work and they work in multiple indications, go after it. As I say to Eric all the time, "I will take care of the financing.

Don't let that slow you down." When I asked people at Merck, Sanofi about Dupixent, KEYTRUDA, all the others, I said, "What would you do differently?" They said, "I'd have gone at all the indications a lot quicker." When I think about that and I think about the fact that we might, then I would say it all depends on circumstance. If we find we have multiple indications we can move, we're not going to say, "Let's just hold that for another calendar year because of a financial." The reason why we can do that, and another question could be, doesn't that give up financial gain, and aren't you giving up some returns? Not really. I mean, it's a rounding error, and let me explain that.

I go back to our gross margin being 55% today, and if we do, and if you've seen the partnerships we've done, the royalties are a low single digit. These are going to be potentially multi-billion dollar products. It makes no difference. It really makes no difference. What makes a difference to value creation is you get a product, you get it to market a year early or as fast as you can in multiple indications. The other thing I'd say, not that I really think about it too much, but Eli reminds me of it sometimes, is you are sharing some of the risk. If we decide to do that going to some indications, then actually it's not just our capital, it's somebody else's capital.

I think for me, it's get great science, make it happen really, really quickly, and if partnerships help us do that, both financially or from a commercial execution, because somebody just could have an extra capability in a certain area. We approach it in maybe a slightly more agile way. Let's get it to the market, let's maximize it as fast as we can, and if we keep doing that, I think we'll have a long runway. Chris, who's next?

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Oh, sorry. Doug is next, then Chris Schott, then Les, and Glen, and Ash, I'll get to you as well, and anyone else on this side.

Douglas Tsao
Analyst, H.C. Wainwright

Hi. Thanks for taking questions. Douglas Tsao , H.C. Wainwright. I guess, Richard, first, the last couple quarters between Emalex and dexmedetomidine, we've seen a couple acquisitions of products. I am just curious just how we should think about M&A in the broader context of everything we heard about today in terms of the innovative pipeline, and sort of the pace of M&A and sort of your appetite. Are you still going to be largely focused on these de-risked assets that are sort of on the cusp of coming to market? Then I have a follow-up question for Eric on duvakitug.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Yeah. So, look, I think if we go back to the key principle, which is bring products to the market as fast as possible that can meet an unmet medical need that we can create value from. As Eric said, I don't know he's the first guy that said it in his position, he means it, we're agnostic to where it comes from. We just relentlessly look at it. By the way, we challenge our organic pipeline all the time. Is it worthy of what's out there? So, we don't look on it through rose-tinted glasses saying, "Okay, we have this. It's a bispecific, it's a dual-specific, it must be really cool." We really critique it, because otherwise it's not going to get the capital.

But yes, we will continuously pursue BD, because that fills in that principle, which is our job is to have a pipeline that's allowing us to have a launch every year as often as we can, which is a very ambitious goal, by the way, and to do that through BD. Is it de-risked or less risk? Well, I suppose it's interesting. Right now, we focus on very much de-risked, and we think if we look hard, we can find some really good assets, and we found those, and they're very synergistic, and I think they have some really good long-term value. We'll always keep pursuing that because it makes a lot of sense. If you can find something de-risked at the right price, I love that. Sometimes you can't, or sometimes we'll understand that the biology and some of the understanding of disease is moving.

So, what we think about our pipeline as de-risked, to Eric's point, is it has a high probability of success. Others may disagree. So, when we look externally and we have the same belief, then we could look at stuff earlier. But once again, it goes back to that continuous evolution of looking at where we're trying to get to, how we're trying to get there, what element of risk we want to take on, and what opportunities that we have for our capital. So, it's very dynamic. But yes, the balance sheet, and Eli showed it. That's the first time you've showed that, actually, $11 billion plus cumulative cash flow. So, we know we have capital coming our way, and we've been planning for this. So, we have started to, in our pipeline of things we assess externally, that has expanded dramatically.

But we've been following opportunities that we knew we could never target three years ago, because we knew this day would arrive, and tomorrow will arrive, and we can target them. But the question always is, do we get them? Can we get them at the right price? If we can, great. If we can't, we won't do it, because we're very disciplined on our capital.

Douglas Tsao
Analyst, H.C. Wainwright

And a follow-up on Duvakitug, and I said, Eric, maybe I'd be curious to hear Chris's perspective as well, in terms of pursuing FSCD. Because I guess, conceptually, if the TL1A does, or if the PTF does what we think it can do, or potentially could, you would see a shrinkage of that market. I'm just curious how you think about what getting labeling for that opportunity would give for you commercially.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

I would love to answer that question. It's okay, Chris. So, I really like the indication for FSCD. Remember, that is the worst of the worst for CD. You saw what David mentioned, it's an obstruction. It's a significant problem that drives a lot of symptomatology, pain, and surgeries in the area. The thing that's, I think, great about it is two things. One, it might prove the point that this class of molecules has a true anti-fibrotic effect, which is novel, it's brand new, it's very exciting to have a molecule like that. But second, it will make a differentiated label for sure. So when you're going on a crowded space, we already have good numbers, but to have that in the label would be head and shoulders above the rest. So that's what gets me really excited about it. You can have a really great label.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah, that pathway obviously is an incredible commercial opportunity, right? When you have highly engaged patients, highly symptomatic, and they're willing to act and advocate for themselves, then we can solve the access and all the other surround things that generally impede their ability to get treated because it is so differentiated.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Thank you, Doug. Chris is next, then I think I promised Les next, and then Ash, and then Glen.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

I see it, Jason.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

I see it. I feel like this is an auction.

Chris Schott
Analyst, JPMorgan

Great. Chris Schott from JP Morgan. Just maybe first on the thicker pipeline, can you just talk a little bit about the slope or cadence of the launch you are expecting here as we consider obviously a huge unmet need, but a new kind of labeled indication? Is this one that we should think about, we have seen other settings where it is a gradual kind of blocking and tackling type launch or something that there could be kind of a more of a bolus or kind of faster kind of ramp once approved? The second one for me is on that earlier stage pipeline. You look at IL-13, TSLP, TL1A, IL-23, and they are very exciting targets, but they are also ones that are being developed by some of your competitors.

You laid out today how these molecules could be differentiated, but can you just talk a little bit about when we will be able to generate data to see if that molecular differentiation is translating into actually kind of improved efficacy versus other programs that are being run elsewhere? Thanks.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Do you want to start?

Chris Fox
EVP, Teva Pharmaceutical Industries

Sure. Great question. Let me tell you, we are modeling this as we speak because we have not given guidance yet. What I would say is, one, this is a perfect place because you know that there is high unmet needs, as we talked about today. Physicians are aware of it. They want something that is indicated for it specifically. What we have to solve for, once we finish our pricing research, which we are on our third round right now, and understanding what that looks like, is the access approach. So, how impeded will fast adoption with patients that want to get on it right away be based on whatever implements are in place? That will come down to our ability to negotiate and have people appreciate the value of the innovation. That is not super predictable, just to be really honest.

Those are hard yards, and we do them all the time because, again, this is why we are vigilant about saying, "We want to have access, but we know we need to preserve the value for the innovation." Otherwise, we have not served anyone very well. We cannot make this repeatable and launch all these great brands if we do not do that.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

So, onto the earlier pipeline and how do we compete? There are some subtle things, and I will make a joke, Steffen, who is a very humble German. There is a lot to what they do in the market, in the molecule development. Let us look at duvakitug first. We made a great antibody. The fundamentals are there, more potent, more selective, low anti-drug antibodies, and then we execute the hell out of the program so that we are in the race, and I think we can beat people.

We are doing the same thing with anti-IL-15, great quarterly dose compound, subcutaneous, great data early on, and we move fast. So that differentiates us. When you look at the molecules that Steffen talked about and how we design them, TSLP/IL-13 is de-risked. There is some fantastic data out there in asthma, but that molecule is fundamentally different from what Steffen talked about.

The boredom of what he showed that the antibodies all look the same, that is an extremely good thing. And I will emphasize that for Steffen, because we can make tons of antibody. The yield from a cell line that is making an antibody is far bigger than these, what we refer to as Frankenstein molecules. So your yield is better, your productivity is better, your immunogenicity is going to be much better. So they look boring, but there is such elegance in the way that they are designed. So, that is how we use the science in our favor to make better molecules that are differentiated, and then we execute the hell out of it. And they are all de-risked. Those are known targets that we are bringing together properly. And like I said, TSLP/IL-13 is already de-risked. The combination of TL1A, which has great safety profile, in combination with these other targets, that data is going to mature.

We know that those two should work. We are going to watch our competition. We will be running in parallel, and we will be able to attack really quickly into the slipstream of those marketed programs. Everything we did not show, the seven other programs, we are all ready for where the ship is going to sail.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Yeah, and maybe I will add there, Chris, is because people combine the same things does not make them the same product with the same capability. And I think Steffen tried to emphasize that. But we look at everything else, and so we know we have to beat what is out there, particularly if it is ahead.

And so, all TSLP/IL-13s really are not the same. Now, we showed that with the TL1A, and that was, I think, something that surprised people. I think with the TSLP/IL-13s and the combinations with TL1A, I think you will start to see that more fundamentally. But we are aware of it. We are aware if you are going to be somewhere behind somebody, you have to be better, and that is where we also said differentiated. But I think the quality of that engineering will start to really play out. So I think that is just one thing to keep in mind.

Les Sulewski
Analyst, Oppenheimer

Thank you. Les here from Oppenheimer. On the BioXcel asset, now 343, what makes at-home use commercially viable? If approved at home use, what supervision or monitoring do you expect on the label, and how would those requirements affect the eligible population group? Maybe if you can walk us through that $500 million peak sales. Then second, on the TSLP/IL-13, what asthma population subgroup do you expect to benefit from that approach, and what signals would that show on the potential of TSLP?

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

So, yeah, so there's a couple on there. So with regards to the label of dexmedetomidine, that's a very important thing. I think there's 7 million people who have agitation from schizophrenia and bipolar disease, and the key is the at-home use. We know actually dexmedetomidine works very well in the in-hospital use. I mean, it's been used. That's not the biggest market. The key is having it at home, because people, when you're even well-controlled on schizophrenia, there are moments where you can get agitation, and then that escalates really quickly. So if you have something at home that you can slip under your tongue, and the data in the phase III studies suggest that you have activity within 20 minutes. That de-escalates someone who's going to go into a relapse, that makes their schizophrenia worse, gets a hospitalization, and makes them refractory to disease.

It's a perfect tuck-in for the population that we're serving with UZEDY and WELTRUZA now. So, that's what's driving the, I think, the value in the label. I'll let Chris comment on anything more about what that opportunity is. I think it's much needed, because what are the options? People either have to go up on their antipsychotic medications higher, or they use a benzodiazepine. Physicians don't want to prescribe benzodiazepines. Dexmedetomidine is a non-addictive, fast-acting film under your tongue that's perfect for someone who's having that crisis. So that's my thoughts about dexmedetomidine.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah, I'll just clarify one thing. So 7 million patients have schizophrenia, bipolar I, and bipolar II. Of those, about 25%-40% have agitation that's persistent enough that they would want to treat it at home. What we've learned from acquisition and understanding this product through the market research that we've done is that it wasn't used very often in a hospital setting, because they have other things. It didn't make sense to have a If someone's in a clinic setting, hospital setting, and they're agitated, they're not going to get some [inaudible] on their tongue. It's going to be something much, much more urgent and severe. So this is the perfect drug for an at-home thing where someone can manage it themselves.

They're absolutely aware when they're agitated, so the fact that the patient can be self-empowered to act, I think this is going to be interesting. We're going to learn a lot more, right? These are early days with this. We're still forming our approach and understanding, but we've done tons of market research that says there's a market out there for this.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Yeah, I think the thing I'd add, take the mic over there. I think the thing I'd add is, you put $500 million in there. We have to do a lot of work to understand. I mean, obviously, there's 2 million, I think it's 2 million - 3 million patients who r ight, get agitation. I think the thing that gives us confidence about making this an optimized asset is the fact that we're in with the psychiatrists every day in all the clinics, in all the offices, talking about UZEDY and WELTRUZA.

I think the fact that we come along with this product, one, gets traction because they give us time because we help them with their patients, and that also, I think, spreads the opportunity of how this could be used at home on scale. But we still have to get to that point. We have to see the label and understand it.

But very synergistic, but also from a share of voice, we can give it a lot of share of voice, even in a third-line detail, because we're Teva in schizophrenia. I think that gives us opportunity. As we've shown, if we think, as we get more accuracy around what sales could be of products, we let you know. That's our sort of early gauge.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

And a quick answer to your TSLP/IL-13. We will run in inflammatory asthma in that POC study, but the most important thing is we have to look at the same population that has been looked at before, so we know it is a killer experiment. Either you are better or you are worse, or we move fast.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Okay. Ash, you go next, then Glen, and then David, hold onto the microphone, and you will be next after that. And then Hannah.

Ashwani Verma
Analyst, UBS

Okay. Ashwani from UBS. Thanks for the presentation today. Maybe on ecopipam, so good to see the $1 billion peak sales potential that you mentioned today. I guess this has very much similarities to how the tardive dyskinesia market formed. So in a way, movement disorder, new market, and I am just curious to compare to that. When you think about it, that was a duopoly, and both drugs did well, and top came out above $2.5 billion, let us say. I think where you are giving the $1 billion sales guidance, is there a lot of conservatism baked into that? And do you think there is a TAM expansion down the road that can happen? And yeah, just curious if this is a starting point and what appropriate revisions would be for that.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

So I will take that one. Actually, Ash, I can remember your first question in 2023 as well, you know? Do you know what your first question was in 2023?

Ashwani Verma
Analyst, UBS

It was my first question.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

It was his first one. It has changed, like I said. Okay. So 1 billion. I think you are saying it is not enough, yeah? You should probably come work for Teva, because that is what we tend to say to each other quite a lot, which is nothing is ever enough. I think there are lots of things to understand, how we can mobilize this, how we can, I think to Chris’s point, access versus value. How do we do it over the time, making sure we get the right value over the long time? How do we mobilize physicians who are not used to having a treatment specifically designed for Tourette’s? There is a lot of market creation. You are right, we are good at that, so that gives us a lot of optimism. Let us see.

As that evolves, as we get deeper understanding, as we understand the market access, whether people have to go through the generic options that have been highlighted, we will come back to you. I suppose what I tend to say, which I say with the utmost courtesy with everybody who models anything on Teva, if you just put in the numbers we put up, then everything looks pretty good anyway. If those numbers change as we get more detail, then it will look just better. I think, let us start with the billion, and then we will work out as we get more understanding, what it could be.

Ashwani Verma
Analyst, UBS

Just one quick follow-up. I wanted to ask about the TL1A/IL-23 bispecific. Why go after this approach as opposed to just combine with the, with the known IL-23? Can you talk about, like, is there any advantages in terms of potency or simultaneous target engagement? If you can share if this is a p19 or p40 selective, that can have an implication on whether it is just going to IL-12 or IL-23 as well.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

Yeah. I think we can divulge what the target of the IL-23 is. It is a p19, so it is the better of the choices that you can go out there. Your other question about combinability. We fundamentally focus on bispecifics, and the reason we do that is doing loose combinations, unless you put it in a combo device, which is not easy to do, it is hard to imagine how you are going to price that in the marketplace. If you put it together in a very well-engineered molecule that actually builds upon what the targets are and how we have engineered it. I must say, when you do a catch and release, the pH-sensitive design that Steffen talked about, think about how remarkable that is. They engineer an antibody that binds it, releases a different pH, gets recycled.

It is almost like an enzyme removing cytokine from it. Those are all advances over the loose combination you could possibly do alternatively. I am happy to watch the loose combinations get studied and see what the safety looks like. I think at the end result, thinking again from the bench side all the way to the marketed product, you have to think about how you are going to price it, how it is going to work, and how it is going to be better.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Thanks, Ash. Okay, Glen is next, then David, then Hannah, then Dan, then Matt. Is there anyone else I am missing? No.

Glen Santangelo
Analyst, Barclays

Thanks. Glen Santangelo from Barclays. Richard, you spent a fair amount of time today talking about capital deployment and where you want to allocate those dollars. I think what stood out to me the most today was the work being done by Steffen's team on those 10 early-stage targets. When you think about 2027 specifically and leaning in terms of incremental R&D expense in that area, how do you think about that versus business development? I heard your answer to an earlier question that that is still very important to you, but, sitting in our seats, we hear every CEO talk about looking for late-stage commercial assets that have already been de-risked that they can bring to market.

How is that market developing from a competitive perspective, and what are you seeing in terms of acquisition multiples for products, and how should we think about that? Then maybe, Eric, I had a question for you regarding the timing of the TL1A top-line data, given that Merck has already announced that they are going to release their data in early 2027. Lastly, and then I will give up the mic, Chris, I was kind of curious about the WELTRUZA launch in 2027 and where you stand from a market access perspective and how, Eli, we should think about that launch trajectory in 2027 so we can manage expectations. Sorry for all the questions.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

That is all right. Thanks, Glen. It took you a long time to get the mic, so I think you took that into account. I think the question was around how do we think about M&A? Obviously, the funding basically for the pipeline, we financially plan three to five years in advance, quite detailed. So we planned for 2027 a while ago, so we are not having to pivot too much. At the same time, if we turn over great data, which maybe Steffen can do, we will move capital quickly, and we move it from inside the business. We find that relatively easy because it is just a return on capital. If something has a better return, then we take it from something that has less return, and that is just how we operate.

Which I think is important because otherwise people just think that we have budgets forever, and you do not. You have a budget based on the fact you will give a return on that. Sometimes you can have more, and sometimes you are going to have less based on the analysis. I think in regard to the BD, yeah, there are a lot of people looking for late-stage assets, but at the same time, I think the way we think we can value some assets is slightly differently.

Sometimes we value them lower, sometimes we value them potentially higher because if you are synergistic to ours. It is super competitive. We look at a lot. I think the scale of what we are going to look at going forward will change a bit, based on breadth, maybe a number of assets we will bring in individual, as well as potentially larger ones.

We will always have that discipline in mind. What do we want to spend, and what return will that give? There comes a point where we walk away. We do that on a very, very regular basis. I think there are a lot of opportunities out there. You just got to work really hard to find them, and we have built quite a muscle on that. So I feel confident on that. Part of it is how our organic pipeline develops as well. I think right now, our trajectory of growth, you saw is organic, is really exciting, but we will add BD to that. We want to underscore it, and we have the capital to do it. So we have to deploy that capital, whether it is internal, whether it is external, or whether it is returning it to shareholders.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

I'll just a quick update on the duvakitug question. Studies enrolling Sanofi, our partner's doing a great job in getting the studies moving at pace. We'll present the induction data as we do in these studies, and then we'll present the maintenance data later. I wouldn't focus on the induction data right now. I'm focused more on when do we do the submission. I think when you look at the overall competitive field, we're well within the 18-month window, where only efficacy makes a difference compared to our competitors for ulcerative colitis. For Crohn's disease, I think we're right in the middle of the pack. In fact, I think we're in a good position on Crohn's. So, that's what I worry about, and making sure that the drug gets approved and has the best data we can possibly get.

Chris Fox
EVP, Teva Pharmaceutical Industries

Yeah, I'll be super quick on WELTRUZA. So, this is right in our wheelhouse because we just did it with UZEDY, obviously. What we're time-bound on is access and getting Medicaid specifically across the country. We have a heat map that we show Richard pretty regularly of when those reviews are state by state, and that will kind of determine the launch trajectory. But we expect to finish 2027 in a pretty positive spot, having most states had a review and determining if it's on or it's not, and then we'll play through the rest of it. But it's a market build situation. It's not going to be like month one. We have feet on the street now, and it's going well.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

David, go ahead.

David Amsellem
Analyst, Piper Sandler

Thank you. David Amsellem from Piper Sandler. So, just a couple for me. First on duvakitug and inflammatory bowel disease, more broadly. Wanted to get your thoughts on the recent SKYRIZI combination data with its alpha-4 beta-7 in Crohn's. That leads me to a bigger picture question about where the IBD space is moving in terms of combination therapies, and what that would imply regarding a monotherapy option that you have with duvakitug once duvakitug reaches the market. So, just help us understand how the transformation of the space, particularly in terms of combination therapies, what that implies commercially for duva. Then on the TSLP program, you talk about asthma. Are you going to look at COPD, and then are you going to look at non-respiratory indications, just given that you have an IL-13 with your TSLPs? Would love to get some more color there. Thank you.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

Yeah, I'll start with the second question first. That will grow. Asthma is the best place to start because it's the lead indication that has a good market potential, but also will define what the efficacy looks like compared to other people who are looking at TSLP/IL-13. It's a great killer experiment to know where you stand. Then we'll use it as a lead indication. We'll probably expand into other things that you mentioned that the Th2 space goes into. That's for that. For duvakitug, monotherapy is what has to be defined. Remember, it's a brand new biologic class. It's the first anti-inflammatory agent with potential anti-fibrotic effect. There's going to be a decade worth of work on monotherapy, and it's going to be very exciting. That will give the option for people who are failing.

Remember, 50% of people on a biologic fail in two years. They're cycling through these things. They need new things. Monotherapy is going to be a very important thing for a pretty long time at this point. We're excited by the potential of combinations. You mentioned some data that's coming out. Over the next 10 years, these things, we're going to learn a lot about what combinations are best, what combinations are safe. We overlook the safety. A lot of people, we love the interest in TL1A, and a lot of people want to combine with it because right now, you can imagine there's probably about 3,000 or 4,000 people on a TL1A right now, and the safety is holding up. That makes it a very nice partner to combine with.

But we need to learn a lot still, and it's going to take some time to get there. I'm very bullish on the fundamentals of duvakitug. Most potent, most selective, lowest anti-drug antibodies, best phase II data numbers posted. That's what we're focused on now, but ready for it. As all these combinations work out, we're going to have a lot of combinations ready to go.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Thank you. Hannah, go ahead.

Hannah Liu
Analyst, Scotiabank

Hi, this is Hannah here from Scotiabank. I had a question about the IL-15 and celiac disease. We have now seen other approaches targeting the IL-15 pathway. Mechanistically, what advantage do you see from targeting the ligand versus targeting the receptor, and what evidence have you seen that this could translate into meaningful differences in safety or efficacy?

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

Yeah. I love the question because it really kind of shows the differentiation of our molecule. In general, our strategy at Teva is always to hit the ligand because that is a little bit cleaner way of doing it. There is nothing wrong with hitting the receptors. There are great examples like duvakitug, but it does tend to have other off-target effects when you are hitting a receptor on the surface of the cell. We just strategically always go for the ligand. Now, the more subtle thing, the more interesting thing is when you hit the ligand, you can actually measure the target engagement by hitting the free cytokine. We almost religiously look at that free cytokine level to help us determine what our dosing is.

That knowledge, we knew immediately that we had the potential to go to quarterly dosing, which is a great advantage, and also told us that we did not necessarily need a loading dose. We knew right off the bat, if you hit the receptor, you cannot measure those things. I mean, there are some other biomarkers you could look at, but there is nothing as precise as this. Figuring out our competitors' dosing schedule is challenging. They have great activity, and it does not look like there is any problem with hitting the receptor right now. But we are in a much better place when it comes to our health authority interactions and our planning and our modeling. Did you have another question I missed? I forgot. Okay, thank you.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Okay, so Dan next, and then Matt. If there is anyone else I am missing, raise your hand.

Dan Clark
Analyst, Leerink

Thank you. Dan Clark from Leerink. First question, you wanted to ask Ash in a little bit of a different way, but what is embedded in the billion-dollar peak sales estimate for ecopipam, just in terms of, you are figuring out price, but roughly where that sits, and maybe positioning versus antipsychotics? Thank you.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Yeah. We are not going to go into sort of details of that, I am afraid. We give some of that when we give guidance, but as Chris said, we are on our third round of pricing, so that is a big part of pricing, and that will help us with the patient population, what could that look like. So, I think bear with us on that one, if you can give us a bit more time.

Dan Clark
Analyst, Leerink

Just another one from me. In terms of duvakitug, I believe it is one of the only anti-TL1As with a subcu induction phase. How do you think about that in terms of differentiation versus what else is out there? Thanks.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

So, yeah. I mean, having subcutaneous is very important. We have done the entire program as subcutaneous. I think there was some confusion early on in the program about IV, but our induction, our loading dose, and our maintenance is all subcutaneous, and actually, it has been a differentiator from the very beginning.

Richard Francis
President and CEO, Teva Pharmaceutical Industries

And by the way, you heard through Steffen's presentation, everything is designed to be subcutaneous because we start with the patient in mind and what we have to differentiate. So, it is not we work out the last minute, and all of his programs are subcutaneous. Is it Matt next? Who is it?

Matt Dellatorre
Analyst, Goldman Sachs

Matt.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Thanks, Dan. Last but not least.

Matt Dellatorre
Analyst, Goldman Sachs

Great. Thank you, Matt. Salveen, Goldman Sachs. Maybe going back to FSCD, it seems like this is probably the most significant test of duva's impact on fibrosis. So, maybe just speak to how positive or negative results there will drive your broader strategy on the fibrosis side, and should we assume you will wait for those results before exploring some of those other fibrosis indications on one of the slides that you shared? Then, just a couple on timelines. On anti-IL-15, I know you highlighted the second half 2027 phase IIb dose-ranging initiation, but it seems like you could move pretty quickly post that, given the unmet need. So, I guess, could we think of maybe an earlier filing than 2034? Then just lastly, when should the TL1A/IL-23 bispecific enter the clinic? Thanks.

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

Well, I will ask you about the last question, but to start off with FSCD, fibrosing Crohn's disease, yeah, it could be a great demonstration of antifibrotic effect. It is a hard nut to crack, though. I mean, that is extensive fibrosis, and no one has been able to achieve that. But if we do, clearly show a benefit in fibrosis, I do not even think you need the biopsy. If you show changes on MREs, looking at that stenotic effect, and maybe if we see some symptomatology that improves, that would be very exciting.

And that would really enhance the label, as I said before, for IBD. That is not going to stop us from doing other things. I mean, we are getting the hidradenitis suppurativa going. That could show antifibrotic effects as well. That is a major component of hidradenitis suppurativa. Then we will be looking at other indications more and more.

This field's going to continue to evolve rapidly, as we see. Both of those will actually show some, hopefully, effects on fibrosis. Your second question was about? IL-15.

IL-15 timelines. We're working through the phase II study design for celiac disease now with FDA. Depending on what that looks like, Richard will be the first one to tell me, "Go faster." I can imagine we're going to be figuring out ways of speeding that up. It is important to remember that we've got the vitiligo up and running at this point, so we're really excited about that. That will drive our first initial market application there. That's how we think about it right now. Your last one, I didn't hear.

Matt Dellatorre
Analyst, Goldman Sachs

TL1A/IL-23 bispecific, when could that enter the clinic, and then what are the preclinical studies?

Eric Hughes
EVP, Global R&D and Chief Medical Officer, Teva Pharmaceutical Industries

It's preclinical right now, so we have to get it through tox, and hopefully we'll get that done pretty soon. The IND for TSLP/IL-13 is being submitted right now. We'll have that in patients beginning of the year, and that'll be healthy volunteers, so that'll go pretty quickly.

Christopher Stevo
Head of Investor Relations, Teva Pharmaceutical Industries

Great. Thank you, Matt. Richard, would you like to make some concluding remarks?

Richard Francis
President and CEO, Teva Pharmaceutical Industries

Yes. Thanks, Chris. Firstly, thank you, everybody, for coming here today. I appreciate you have other places you could be, and you chose to be here, so thank you for that, and I hope you found it rewarding and informative, and that will lead to more discussions. I want to thank my team who are up here today, and some who, David and Steffen, who presented. I think what's been achieved at Teva in less than four years is because we have a great team, great leadership throughout the company, a great culture. To the people who are in Teva who are watching, thank you as well, because we get to present the data, what we're doing, but it really has taken 30,000 people to work very quickly, and with urgency to be here today to present what I think is an impressive company with an impressive future.

Also like to thank the team who put this together. We do a lot of things at Teva in parallel, and some of the people who helped us put this program together were doing other things as well at the same time, so I thank them as well. With that, I conclude Teva's first-ever R&D Day, and I look forward to maybe having more R&D Days together with you in the not-too-distant future. Thank you.